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remodel extracellular matrix (ECM) in primary tumor and metastatic microenvironments, exerting both 
pro- and anti-tumorigenic effects. However, the intrinsic mechanisms that regulate the activation of 
fibroblasts are not well defined. The signaling axis comprising the calcium-activated Ser/Thr phosphatase 
calcineurin (CN), and its downstream target nuclear factor of activated T cells (NFAT), has been shown to 
play important roles in in endothelial and immune cell activation, but its role in fibroblasts is not known. 
We have shown that deletion of CN in fibroblasts in vitro results in alterations in fibroblast morphology 
and function consistent with an activated phenotype relative to wild-type fibroblasts. CN-null fibroblasts 
have greater migratory capacity, demonstrate increased collagen secretion and remodeling, and promote 
more robust endothelial cell activation in vitro. ECM generated by CN-null fibroblasts contain more 
collagen with greater alignment of fibrillar collagen compared to wild-type fibroblast-derived matrix. 
These differences in matrix composition and organization impose distinct changes in morphology and 
cytoskeletal architecture of both fibroblasts and tumor cells that may represent changes in their 
biological function, e.g. activation or epithelial-mesenchymal transition. However, while they are more 
activated at baseline, Cn-/- fibroblasts cannot functionally respond to TGF-beta stimulation in multiple 
activation assays. They are also unable to upregulate FAP on soft, fibronectin-coated substrates to the 
same extent as WT fibroblasts. Consistent with this in vitro phenotype, we show that mice with stromal 
CN deletion exhibit a greater incidence and larger lung metastases. Our data suggest that CN/NFAT 
signaling contributes to the maintenance of fibroblast homeostasis and that loss of CN/NFAT signaling is 
sufficient to promote fibroblast activation, leading to the outgrowth of lung metastases. With a better 
understanding of how CN affects fibroblast homeostasis, new therapeutic targets may be identified that 
prevent the priming of the metastatic niche. 
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ABSTRACT 
 
THE ROLE OF CALCINEURIN/NFAT SIGNALING IN FIBROBLAST 
HOMEOSTASIS AND ACTIVATION 
Allyson Lieberman 
Dr. Ellen Puré and Dr. Sandra Ryeom 
Fibroblast activation is a crucial step in tumor growth and metastatic progression; activated 
fibroblasts remodel extracellular matrix (ECM) in primary tumor and metastatic 
microenvironments, exerting both pro- and anti-tumorigenic effects. However, the intrinsic 
mechanisms that regulate the activation of fibroblasts are not well defined. The signaling 
axis comprising the calcium-activated Ser/Thr phosphatase calcineurin (CN), and its 
downstream target nuclear factor of activated T cells (NFAT), has been shown to play 
important roles in in endothelial and immune cell activation, but its role in fibroblasts is 
not known. We have shown that deletion of CN in fibroblasts in vitro results in alterations 
in fibroblast morphology and function consistent with an activated phenotype relative to 
wild-type fibroblasts. CN-null fibroblasts have greater migratory capacity, demonstrate 
increased collagen secretion and remodeling, and promote more robust endothelial cell 
activation in vitro. ECM generated by CN-null fibroblasts contain more collagen with 
greater alignment of fibrillar collagen compared to wild-type fibroblast-derived matrix. 
These differences in matrix composition and organization impose distinct changes in 
morphology and cytoskeletal architecture of both fibroblasts and tumor cells that may 
represent changes in their biological function, e.g. activation or epithelial-mesenchymal 
transition. However, while they are more activated at baseline, Cn-/- fibroblasts cannot 
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functionally respond to TGF-b stimulation in multiple activation assays. They are also 
unable to upregulate FAP on soft, fibronectin-coated substrates to the same extent as WT 
fibroblasts. Consistent with this in vitro phenotype, we show that mice with stromal CN 
deletion exhibit a greater incidence and larger lung metastases. Our data suggest that 
CN/NFAT signaling contributes to the maintenance of fibroblast homeostasis and that loss 
of CN/NFAT signaling is sufficient to promote fibroblast activation, leading to the 
outgrowth of lung metastases. With a better understanding of how CN affects fibroblast 
homeostasis, new therapeutic targets may be identified that prevent the priming of the 
metastatic niche. 
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CHAPTER 1: GENERAL INTRODUCTION  
 
Metastatic disease is responsible for 90% of total cancer deaths1; despite significant 
advances in cancer treatment over the past few decades, the 5-year survival rate of patients 
whose tumors have metastasized to distant organ sites is still much lower than that of 
patients whose tumors have not spread2. Given that most cancers have likely already spread 
at the time of diagnosis3, it is of utmost importance that metastatic disease be further 
investigated, and new targets identified.  
There have been many efforts to identify specific factors or signaling pathways in 
tumor cells in order to better target tumor cells and successfully prevent and/or treat 
metastases. However, these modalities are often complicated by the fact that the increased 
proliferation and mutation rates of cancer cells facilitate the development of resistance to 
targeted therapies4. Thus, the tumor microenvironment (TME) has become an increasingly 
appealing target of study. The concept that the surrounding microenvironment might affect 
a tumor cell’s ability to colonize and grow in a certain tissue has existed since 1889, when 
the surgeon Dr. Stephen Paget hypothesized that metastatic growth in a specific organ 
requires both the “seed,” the tumor cell, as well as the “soil,” a permissive 
microenvironment5. It is increasingly clear, too, that the microenvironment of the distant 
site is “primed” for metastasis prior to metastatic colonization6. Since Dr. Paget’s original 
hypothesis, numerous studies have characterized the role of different cellular 
compartments of the microenvironment – the blood and lymphatic vasculature, the immune 
system, and the stroma – in tumor growth and progression (Figure 1.1). These findings 
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have led to the development of a number of therapies targeting the microenvironment with 
varying degrees of success. 
 
 
The microenvironment is crucial to tumor growth and progression 
The endothelium, angiogenesis and tumor growth 
Blood and lymphatic vessels are crucial in tumor formation, as tumor cells are 
rapidly growing and highly metabolically active, requiring a large amount of oxygen and 
nutrients to support their growth. As they grow, the metabolic demand of tumors quickly 
outstrips their vascular supply, which leads to intratumoral hypoxia and acidosis. These 
changes in turn trigger blood vessel formation via the activation of hypoxia inducible 
factors (HIF); this induction of angiogenesis is often referred to as the “angiogenic 
switch7.” However, the constant, pathologic activation of angiogenic pathways without a 
resolution phase leads to the formation of abnormal blood vessels; tumor vasculature is 
Figure 1.1: Overview of the three major compartments of the tumor microenvironment and 
their roles in tumor growth and progression. 
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often characterized by its increased vascular permeability (i.e. leakiness) and irregular 
architecture when compared to normal vasculature8. This increased, abnormal 
angiogenesis originally made it an appealing target for cancer drug development.  
Some anti-angiogenic therapies have shown efficacy in specific cancer types, but 
by and large, efforts to target tumor vasculature have not been as successful as initially 
hoped. Anti-VEGF antibodies have been approved for use as a first-line therapy in only a 
small number of cancers, including glioblastoma multiforme, colon cancer, and renal 
carcinoma. Although anti-angiogenic therapies often lead to an increase in progression-
free survival, their effects on overall survival are significantly more modest or nonexistent, 
and discontinuation of the drug may lead to “rebound vascularization” and subsequent 
worsening of tumor growth9,10. The use of anti-VEGF therapy is also complicated by 
significant adverse effects, including gastrointestinal perforation, thrombosis, and 
hypertension11. 
 
The immune system and immune surveillance 
Equally important, and a current topic of particular interest in cancer therapeutics, 
is the immune system. In order for tumors to grow, they must evade immune surveillance 
despite an overall increase in inflammation, inflammatory cytokines, and tumor infiltrating 
lymphocytes. This is accomplished through a variety of mechanisms. First, they can 
downregulate the antigens they process and present, thus avoiding detection by immune 
cells. Tumors can also induce the recruitment of suppressive immune cells such as 
regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC) by secreting anti-
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inflammatory cytokines, or by expressing inhibitory ligands that suppress T cell 
activation12.  
Two main strategies are currently being investigated to take advantage of the 
immune system in cancer therapy: immune checkpoint inhibitors and engineered T cells. 
The use of immune checkpoint blockade via CTLA-4, PD-1, or PD-L1 inhibitors seeks to 
re-activate tumor cell-reactive T cells by blocking their regulatory signals13. Checkpoint 
inhibitors have recently been approved for use in metastatic melanoma, prostate, lung, and 
pancreatic cancers, among others and have shown efficacy; their use in other cancer types 
is currently being investigated12. The second immune therapy currently under extensive 
development is the use of chimeric antigen receptor-expressing T cells (CAR-T cells), in 
which a patient’s T cells are virally transduced with a chimeric antigen receptor that directs 
cell killing to an antigen of interest, then re-introduced to the patient. Currently, CD19-
specific CAR-T cell therapy is in use for patients with B cell malignancies (leukemia and 
lymphoma), with many patients achieving complete and durable remission14. However, 
clinical trials utilizing a wide variety of tumor antigens are underway, with varying degrees 
of success and side effect profiles based on the tumor antigen used15. While CAR-T cells 
appear to be a promising and powerful tool in cancer treatment, they are limited to cancers 
with a targetable, surface-expressed tumor antigen that is broadly expressed across tumor 
cells while being specific enough to prevent significant off-target effects.  
 
The tumor-associated stroma 
The third main component of the microenvironment, and the focus of my thesis 
project, is the stroma, a term that encompasses the structural component of an organ or 
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tissue broadly consisting of extracellular matrix (ECM), the blood vessels/nerves supplying 
the organ, and several cell types such as fibroblasts, pericytes, and certain immune cells. 
The stroma is of particular interest as it undergoes marked changes upon tumor initiation 
and progression that can be both pro- and anti-tumorigenic16. These will be discussed in 
further detail in later sections; tumor-associated stroma is generally characterized by 
increases in and re-organization of ECM, an increase in cell density consisting primarily 
of fibroblasts and immune cells, and an overall pro-inflammatory milieu.  
The stroma supports tumor cell growth and invasion, but it also participates in 
significant crosstalk with the immune and endothelial compartments of the 
microenvironment. Cancer-associated fibroblasts have been shown to alter the immune 
system in ways that both promote and suppress tumor growth, through both direct 
interactions with immune cells as well as secretion of a number of pro- and anti-
inflammatory cytokines17. Depletion of aSMA+ myofibroblasts in a mouse model of 
pancreatic cancer decreased immune surveillance by increasing the number of intratumoral 
regulatory T cells, ultimately resulting in greater invasiveness and mortality18. Recent work 
in breast cancer identified four distinct subsets of CAFs with opposing effects on tumor 
immunity and demonstrated differential accumulation of each of these populations in 
different subtypes of breast cancer19.  
Similarly, fibroblasts have been shown to enhance angiogenesis in both in vitro co-
culture assays as well as in murine models of tumor growth20,21. Fibroblasts can support 
angiogenesis via a number of mechanisms, including upregulation of pro-angiogenic 
factors such as HGF or VEGF22,23, downregulation of anti-angiogenic factors such as 
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thrombospondin-124,25, and deposition/remodeling of extracellular matrix26,27. While 
tumor-associated, proliferative fibroblasts are considered to be pro-angiogenic, some 
evidence suggests that fibroblasts may switch to an anti-angiogenic secretory phenotype as 
they become quiescent in the setting of serum depletion28.  
These interactions with other components of the microenvironment have important 
implications for cancer therapeutics. For example, targeted deletion of FAP+ activated 
fibroblasts has been shown to potentiate the response to anti-PD-L1 immunotherapy in 
pancreatic cancer in a CXCL-12-dependent manner, suggesting that the stroma is partially 
responsible for resistance to these therapies29. The stroma has also been implicated in 
resistance to anti-angiogenic therapy, both via the secretion of pro-angiogenic factors as 
well as deposition of matrix proteins such as periostin30,31. 
Currently, clinically approved treatments exist that target or co-opt the endothelium 
and immune system. However, drugs targeting the stroma are less well developed, though 
several clinical trials are in progress. Thus far, attempts to target cancer-associated 
fibroblasts (CAFs) have fallen into two categories: inhibiting their enzymatic function and 
eliminating them entirely. Unfortunately, however, inhibitors targeting several markers of 
activated fibroblasts, including fibroblast activation protein (FAP) and matrix 
metalloproteinases (MMPs), have shown little to no clinical efficacy despite promising 
results in mouse models32,33. Depleting tumors of cancer-associated fibroblasts has shown 
some promise in preclinical studies and is currently being tested clinically. We and others 
have designed CAR-T cells specific for CAF surface markers such as FAP, and studies in 
mouse models of pancreatic cancer show that depletion of activated fibroblasts disrupts the 
desmoplastic response and can improve chemotherapeutic efficacy34. However, the 
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heterogeneity of cancer-associated fibroblasts means that not all CAFs will be eliminated; 
identifying the most influential subpopulation of fibroblasts in a particular cancer will be 
crucial to the success of this treatment modality.  
Additionally, activated fibroblasts play a key role in the maintenance of normal 
tissues, and targeting CAFs may have significant side effects. One method of reducing off-
target toxicity is to select an activated fibroblast marker such as FAP that is minimally 
expressed in normal tissues in order to minimize effects on normal tissue35,36. Our lab has 
shown that targeting FAP+ cells using CAR-T cells causes only minimal off-tumor 
toxicity37.  That having been said, one study in mice demonstrated that depletion of FAP+ 
stromal cells in mice led to significant cachexia and anemia due to the prevalence of these 
cells in normal skeletal muscle and bone marrow38. Even if normal tissues at baseline are 
relatively unaffected by these therapies, targeting activated stroma may lead to an inability 
for tissues to respond to external stressors. While activated fibroblasts play an important 
role in pathologic processes such as tumor growth and fibrosis, they are also crucial to 
physiologic processes such as wound healing and normal tissue remodeling39,40. In diseases 
such as cancer, which can be managed both surgically and medically, targeting of activated 
fibroblasts may lead to increased surgical morbidity due to alterations in inflammation and 
wound healing. 
There is also interest in targeting the ECM itself; current studies have focused on 
pancreatic cancer, a cancer type known for its significant desmoplasia. Excessive amounts 
of hyaluronic acid lead to high interstitial fluid pressure within the tumor, in turn limiting 
chemotherapeutic accessibility. Consequently, treatment of in vivo mouse models of cancer 
with a pegylated form of hyaluronidase (PEGPH20) increases the efficacy of chemotherapy 
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and improves tumor response41. Clinical trials of PEGPH20 in patients with advanced 
hyaluronan-high pancreatic cancer are currently underway and show promise in terms of 
response rate and progression-free survival42. However, this treatment will only have 
significant effects in hyaluronan-dense tumors, meaning that it will be ineffective in a large 
number of cancers.  
Targeting the stroma is an attractive target because of the potential to be widely 
applicable across multiple cancer types; however, much research still needs to be done for 
these targeted therapies to be effective. One of the reasons that stroma-targeting therapies 
have only been partially successful thus far is because the mechanisms informing the 
activation and formation of tumor-associated stroma are not well understood in comparison 
to the endothelium and immune system. While many activating stimuli have been 
identified, and the changes in activated stroma characterized, the molecular mechanisms 
causing stromal activation are largely unknown. Thus, previous therapeutic efforts have 
focused primarily on targeting specific surface markers or extracellular matrix components 
as opposed to blocking or reversing the activation of the stroma itself. To deprogram 
activated, cancer-associated stroma effectively requires a better understanding of how it is 
activated in the first place. I will next briefly review and discuss what is known regarding 
the two major components of the stroma: the extracellular matrix and the fibroblasts that 
secrete and remodel it.  
The extracellular matrix  
The extracellular matrix is a hydrogel that consists of a variety of matrix proteins, 
proteoglycans, and polysaccharides organized in a way that lends structure to the organ or 
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tissue it supports (Table 1.1). Two main types of ECM exist in tissues: the basement 
membrane, which largely consists of type IV collagen and serves as a barrier and basal 
layer for epithelial cells, and the interstitial ECM, which provides a supportive medium 
between cells in a tissue43. Together, these form a scaffold and provide anchoring points 
for the numerous cell types and structures within an organ. 
One of the most abundant components of the interstitial ECM is collagen, 
specifically the fibrillar collagens such as types I, II, III, and VI44. Collagen is secreted in 
an immature form and must undergo multiple proteolytic processing steps and post-
translational modifications in order to form mature collagen fibrils44,45. Crosslinking of 
collagen fibrils is crucial to the overall architecture of collagen; large amounts of crosslinks 
lead to the linearization of collagen fibers, a process that is often mediated by proteins such 
as lysyl oxidase (LOX)44. Once mature fibrils have been established, they can be 
proteolytically processed by the collagenase family of matrix metalloproteinases such as 
MMP1 and MMP8, whereas denatured collagen is processed by the gelatinases such as 
MMP2 and MMP9; this processing can degrade collagen, release bioactive fragments, or 
help to change its architecture and re-orientation46. We have also shown that FAP is capable 
of cleaving fibrillar collagen, but only after it has been processed into ¼ and ¾ fragments 
by collagenases such as MMP147. Apart from collagen, other abundant macromolecules in 
the interstitial ECM include fibronectin, tenascin C, hyaluronic acid and other 
glycosaminoglycans, and periostin43. There are significant interactions between different 
matrix proteins; for example, collagen binds to fibronectin and increases its rigidity, thus 
improving the affinity of fibronectin for its receptors44.  
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Components of Interstitial ECM 
Fibrillar collagens (I, II, III, V, VI, XI, XXIV, 
XXVII) 
Fibronectin 
Elastin 
Laminin 
Hyaluronic acid 
Tenascin C 
Periostin 
Proteoglycans (heparan, chondroitin, keratan 
sulfate) 
Fibrin 
 
 
Apart from its roles in tissue integrity and architecture, the ECM is crucial to 
cellular function within a tissue by transducing signals through several methods. First, the 
organization and composition of the matrix informs its mechanical stiffness, and this 
stiffness in turn can activate signaling pathways such as FAK and YAP/TAZ in a number 
of cell types, including fibroblasts48. The matrix proteins themselves can engage cell 
surface receptors, most notably integrins. The binding of matrix components to integrins 
can differ depending on the size of the matrix fragment or its conformation; one major 
example is the increased affinity of integrin a1b1 to monomeric over mature fibrillar type 
I collagen, implicating its role in early collagen fibrillogenesis49. This allows the ECM to 
inform cell signaling based on its structural properties44,50. Finally, the ECM can be a 
source of growth factors, cytokines, and chemokines. Matrix proteins can sequester certain 
growth factors by binding to them; these growth factors can then be released upon 
proteolysis of the matrix51. Further, proteolytic processing of the matrix can release 
bioactive fragments of the matrix itself. One such example is endostatin, which is a C 
terminal fragment of type XVIII collagen with substantial anti-angiogenic properties52.  
Table 1.1: Common components present in 
interstitial extracellular matrix. 
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The ECM plays many crucial roles in disease processes such as fibrosis and cancer. 
In most solid tumors, the matrix undergoes several changes over the course of tumor 
progression, transitioning from a fibrin- and fibronectin-rich “provisional matrix” to a 
desmoplastic, fibrillar collagen-rich environment53. One of the ways this progressive 
remodeling of ECM can be identified is via tumor-associated collagen signatures (TACS), 
which were first defined in mammary tumor progression (Figure 1.2). TACS-1, 
corresponding to pre-malignant lesions, represents an increase in total collagen signal. 
TACS-2, seen in early tumor growth, occurs when these collagen fibers begin to linearize, 
oriented parallel to the tumor boundary and constraining the edges of the tumor, due to a 
combination of proteolytic processing, crosslinking, and contractile forces exerted by 
tumor-associated fibroblasts. Finally, TACS-3, observed in invasive cancers, occurs when 
these linear collagen fibers become re-oriented in a perpendicular fashion to the tumor 
boundary54. These alterations in collagen architecture have been shown to have both pro- 
and anti-tumorigenic properties. TACS-3-like collagen signatures are thought to 
specifically promote invasion: in tumor tissues, these linear, perpendicular collagen fibers 
serve as a scaffold along which invasive tumor cells can escape and enter the interstitium55.  
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Fibroblasts are a key component of the stroma and are activated in both physiologic 
and pathologic states 
Fibroblasts are the cell type in the microenvironment that is primarily responsible 
for secreting and remodeling ECM in both normal and diseased tissues. They have been 
identified as key mediators of many of the phenotypes present in tumor-associated stroma, 
specifically via their activation. Fibroblasts are cells of mesenchymal origin; one difficulty 
inherent in their study is the fact that no one universal and specific marker defining the 
fibroblast population has yet been identified, unlike, for example, CD31 in endothelial 
cells. Fibroblasts are known to express vimentin due to their mesenchymal origin, as well 
as CD90/Thy1; however, neither of these markers is specific to fibroblasts and must be 
used in combination with other markers such as CD45 as well as contextual clues, i.e. their 
location in a specific tissue. Despite its name, the expression of fibroblast-specific protein 
1 (FSP1)/S100A4 is not limited to fibroblasts, as it has been observed to be expressed in a 
Figure 1.2: Tumor-associated collagen signatures (TACS) during 
tumor progression. Reproduced from Malik et al, Trends Biotechnology 
2015. 
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variety of cell types, including hematopoietic cells, endothelial cells, and vascular smooth 
muscle cells56. On the other hand, markers such as fibroblast activation protein (FAP) and 
alpha-smooth muscle actin (aSMA) are generally expressed only by activated fibroblasts, 
which omits a large percentage of fibroblasts in tissue. Due to the lack of a universal 
fibroblast marker, the isolation of fibroblasts is generally performed through a functional 
property, by selection for adherent cells, and are characterized by their spindle-shaped 
morphology in combination with one or more of the markers described above57.  
The majority of tissue-resident fibroblasts are quiescent and un-activated, with the 
exception of dermal fibroblasts, which express a small amount of FAP at baseline. Tissue-
resident fibroblasts generally have very low proliferation rates and may contribute to a 
small amount of baseline ECM secretion and remodeling, but they are otherwise relatively 
mitotically and transcriptionally inactive57. When these quiescent fibroblasts are exposed 
to disease-related stimuli, however, they undergo a process of activation that leads to 
drastic changes in their function. Before describing the phenotypes associated with 
fibroblast activation, it is important to note that activated fibroblasts represent a 
heterogeneous population. Some of this may be due to the fact that they have multiple 
cells/tissues of origin58. In addition, gene expression-related profiling often reveals a large 
number of distinct, yet overlapping, cell populations that fall under the category of 
activated fibroblasts59. Cancer-associated fibroblasts have proven to be a particularly 
heterogeneous population, with studies revealing many distinct subpopulations of 
fibroblasts in a variety of cancers60–63. Thus, when considering activated fibroblasts, it is 
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important to profile a variety of their functions to determine the specific functional 
phenotypes they represent.  
Fibroblast activation is functionally defined by several changes (Figure 1.3). Given 
their heterogeneity, activated fibroblasts can exhibit one or many of these changes, and 
specific subpopulations often select for a specific subset of these functions. They can 
increase their proliferation, thus at least partially accounting for the increased number of 
fibroblasts seen in diseased tissues. They undergo cytoskeletal reorganization and a change 
in morphology; their migratory capacity increases dramatically. They deposit large 
amounts of ECM, especially collagen, and remodel existing matrix, leading to re-
orientation of collagen fibers. Finally, they secrete a wide variety of cytokines, 
chemokines, and other molecules that can have effects on immune, endothelial, and tumor 
cells as well as having autocrine effects to amplify fibroblast activation57,64,65. 
Fibroblast activation plays a critical role in a variety of both physiologic and 
pathologic processes. In normal wound healing, dermal fibroblasts transdifferentiate into 
myofibroblasts in order to assist in wound closure and remodel the matrix in the developing 
Figure 1.3: Schematic of the activation and function of fibroblasts in pathologic and 
physiologic states. Adapted from Kanasaki et al, Frontiers in Endocrinology 2013. 
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scar66. When this process is deregulated, it can lead to the development of keloid scars, 
benign hyperproliferative lesions that are difficult to treat, have a high recurrence rate, and 
can significantly negatively affect quality of life. Histologic analysis of keloid scar tissue 
demonstrates an increase in fibroblast proliferation, extracellular matrix production, and 
invasion into surrounding healthy tissue compared to normal wound healing. Further, 
evidence suggests that FAP may be crucial to the development of keloids by promoting 
invasiveness in keloid fibroblasts67. Apart from their role in dermatologic processes, 
activated fibroblasts also play an important role in the initiation and progression of fibrotic 
disease in a variety of organs, including the lung, liver, and kidneys. Activated fibroblasts 
in the tumor microenvironment, often called cancer-associated fibroblasts (CAFs) in this 
setting, are major contributors to tumor progression and metastasis. Tumors have often 
been described as “wounds that do not heal” due to the fact that much of the tumor stroma 
closely resembles that of healing wounds that, unlike normal wound healing, do not resolve 
over time53. In the setting of cancer and metastasis, activated fibroblasts are generally 
considered to be pro-tumorigenic; conversely, normal fibroblasts can be tumor-
preventative, thus making fibroblast activation a requirement for tumor progression68,69.  
A wide variety of fibroblast-activating stimuli have been identified. These can be 
separated into several sub-groups: mechanical forces such as elastic stretching or changes 
in substratum stiffness; secreted factors and cytokines such as TGF-b, PDGF, and IL-6; 
ECM composition and contents of the substratum; and cellular stress/damage such as 
reactive oxygen species (ROS)57. Of note, different stimuli may also select for specific sub-
populations of activated fibroblasts. Our lab has previously shown that the levels of FAP 
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and aSMA differ greatly depending on which growth factors and/or chemokines are added; 
furthermore, alterations in the content and/or stiffness of the ECM are sufficient to direct 
pulmonary fibroblasts toward either a FAP+, secretory fibroblast state, or an aSMA+, 
myofibroblast state60. 
Though the activating stimuli of fibroblasts have been well-profiled, the molecular 
mechanisms that underlie fibroblast activation are less well known. A number of signaling 
pathways, especially those downstream of the ligands Notch and Sonic hedgehog (Shh), 
have been of particular recent interest in the modulation of the CAF phenotype57. Loss- 
and gain-of-function studies have identified the epithelial-to-mesenchymal transition 
marker Twist1 as crucial to the function of pancreatic cancer-associated fibroblasts70. 
While many of these signaling pathways have been shown to be sufficient to induce a CAF-
like state, it is unclear which of these mechanisms are specifically required for fibroblast 
activation.  
Fibroblast quiescence: how the un-activated state is maintained 
Current understanding of cell quiescence argues that it is not a dormant or default 
state but rather an active cell state that requires maintenance. As opposed to irreversible 
dormant states, quiescence must be quickly reversible, which requires that the cell be 
primed for re-entry into a more transcriptionally active and/or proliferative state. 
Homeostasis often involves the maintenance of a specific biologic value (e.g. gene 
expression levels) within a certain range and not necessarily at a fixed point, a process 
requiring the constant expression and function of molecular sensors71. Furthermore, in 
order for cells to exit the homeostatic steady state, they must achieve a certain “activation 
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energy” that allows them to enter an unstable transition state prior to activation, 
differentiation, and/or proliferation72. Cellular homeostasis and quiescence have been 
studied extensively in stem cells, a cell type in which the maintenance of the quiescent, 
undifferentiated state is crucial to proper tissue renewal. The loss of homeostatic regulators 
of hematopoietic stem cells, such as folliculin, leads to bone marrow failure due to 
uncontrolled differentiation and lack of self-renewal, suggesting that the “energy barrier” 
to differentiation maintained by this regulator is removed73. 
Compared to many other cell types, fibroblasts exhibit significant phenotypic 
plasticity and are able to tightly regulate the transition between multiple cellular states 
throughout disease progression74. This plasticity suggests that the “quiescent state” of 
tissue resident fibroblasts may in fact represent a steady state of constant, dynamic changes 
in gene expression, contractility, and motility. One study examining the forces exerted by 
spreading fibroblasts on a fibronectin substrate demonstrated that fibroblasts have the 
ability to maintain tensional homeostasis within a specific range via “tensional buffering,” 
a process in which fibroblasts exert variable forces on the substrate in order to maintain 
steady state tension75. Quiescent fibroblasts exhibit significant levels of metabolic activity 
despite their relatively low transcriptional activity, suggesting that fibroblast quiescence is 
actively maintained76. Interestingly, some evidence suggests that quiescent fibroblasts may 
be more capable of promoting inflammation, as measured by greater levels of 
cyclooxygenase-2 expression in response to IL-1b stimulation, compared to proliferating 
fibroblasts77. 
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The mechanisms that maintain the quiescent, un-activated state in tissue-resident 
fibroblasts are still largely unknown. Few markers that specifically delineate the quiescent 
fibroblast state versus the activated fibroblast have been identified; an un-activated 
fibroblast is most frequently defined by its lack of activated fibroblast-associated markers 
and functions. A 2016 review of the role of fibroblasts in cancer suggested that FSP1 is a 
specific marker of quiescent fibroblasts57; however, there is little to no literature evidence 
to support this claim. One recent study used cell-surface phenotyping to identify CD36 and 
CD97 as markers of quiescent lung fibroblasts; they showed that its expression in primary 
lung fibroblasts was attenuated with TGFb-induced myofibroblast differentiation and did 
not overlap with aSMA expression78.  
There is some evidence that specific factors are capable of either maintaining 
quiescence and/or blocking fibroblast activation. Prostaglandin E2 (PGE2) has several anti-
fibrotic effects mediated by the multiple signaling pathways downstream of the E-
prostanoid 2 receptor79–81. Additionally, secreted protein acidic and rich in cysteine 
(SPARC) modulates myofibroblast differentiation and ECM secretion in response to TGF-
b, though its specific role in fibrotic disease is complex, encompassing both pro- and anti-
fibrotic effects82–84. Alterations in substratum stiffness have also been shown to be 
sufficient to “deprogram” myofibroblasts, transitioning from a more activated to a less 
activated state. One group utilized polyacrylamide hydrogels whose stiffness could be 
decreased by ultraviolet light-induced depolymerization. Valvular fibroblasts cultured on 
stiff (32 kPa) hydrogels express aSMA and otherwise display a myofibroblast phenotype; 
when these stiff hydrogels are softened via depolymerization, the fibroblasts cultured on 
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them lose their aSMA expression and myofibroblast phenotype85. Notably, however, we 
have shown that fibroblasts initially cultured on 20-25 kPa (stiff) polyacrylamide hydrogels 
and passaged onto 2-5 kPa (soft) hydrogels switch from an aSMAhi to a FAPhi phenotype, 
suggesting that a decrease in mechanical stiffness to a less pathologic but still 
supraphysiologic value alters the phenotype of fibroblasts to a non-myofibroblast but still 
functionally activated state. This suggests that the loss of myofibroblast markers observed 
upon UV-induced depolymerization may not represent complete deprogramming but 
instead a shift in their activated fibroblast phenotype. Finally, several studies have 
identified small molecule inhibitors capable of preventing fibroblast activation. 
Nintedanib, a multikinase inhibitor that has been approved for use in non-small cell lung 
adenocarcinoma, is capable of blocking TGF-b1-induced myofibroblast differentiation and 
pro-tumorigenic function in tumor-associated fibroblasts86,87. The drug Minnelide has also 
been shown to inhibit fibroblast activation in the setting of PDAC through mechanisms 
that are currently incompletely defined88.   
While anti-fibrotic factors and drugs have been identified, little is known about the 
molecular mechanisms that maintain the quiescent fibroblast phenotype. It is clear that the 
quiescent fibroblast state consists of more than a simple arrest in proliferation, and the 
fibroblast-intrinsic processes that actively maintain their quiescence in terms of functional 
activation are not well defined. The tumor suppressor p53 has been shown to play an 
important role in the tumor suppressive effects of normal fibroblasts; however, p53-
regulated transcription is drastically changed in cancer-associated fibroblasts, instead 
supporting the CAF phenotype89. Some signaling pathways have been found to be 
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downregulated in CAFs in certain cancers; the Notch effector CBF1, Suppressor of 
Hairless, Lag-1 (CSL) has been shown to regulate fibroblast homeostasis through direct 
interactions with p5390. In many dermatologic malignancies, CSL activity, and 
subsequently fibroblast quiescence, is reduced via the downregulation of androgen 
receptor, which interacts with CSL in order to restrain the activation of CAFs through 
transcriptional repression91. Cellular quiescence in fibroblasts may also rely on paracrine 
signaling from other compartments of the microenvironment, particularly normal 
epithelium92. 
Calcineurin/NFAT: a signaling axis responsible for both activation and quiescence 
in a number of cell types 
One signaling pathway that has been implicated in several cell types in the tumor 
microenvironment is the axis consisting of calcineurin (CN) and its canonical targets, the 
nuclear factor of activated T cells (NFAT) family of transcription factors (Figure 1.4). 
CN/NFAT was first identified as a regulator of T cell activation but has since been shown 
to play a role in a variety of cell types. CN is a calcium-regulated serine-threonine 
phosphatase that consists of two subunits: a catalytic (calcineurin A) and a regulatory 
subunit (calcineurin B)93. Upon increased calcium flux into the cytoplasm, calcineurin is 
activated through a conformational change, exposing its catalytic site. The best-known 
substrates of CN are the NFAT family of transcription factors, which translocate to the 
nucleus upon their dephosphorylation by CN and transactivate tissue-specific genes. NFAT 
exists in 4 canonical isoforms, known as NFAT1-4 or NFATc1-4. NFAT5 shares 
homology with the other NFAT isoforms but is not activated by calcineurin. All NFAT 
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isoforms alone display weak DNA-binding capabilities; thus, they require a more strongly 
DNA-binding transcriptional co-activator or co-repressor for effective signal 
transduction94.  
 
CN signaling has been shown to play a crucial role in both tumor cells and their 
microenvironment. Interestingly, individuals with Down syndrome, who due to trisomy 21 
have 3 copies of the endogenous CN inhibitor Down syndrome critical region 1 (DSCR1), 
have a lower incidence of solid tumors than the general population, though they have a 
higher incidence of leukemias95–97. This is thought to be due to decreased angiogenesis 
secondary to an increase in inhibition of the calcineurin-mediated response to VEGF 
signaling, as well as increased inhibition of calcineurin leading to impaired cell cycle 
progression and, consequently, tumorigenesis98–100. On the other hand, transplant patients 
receiving cyclosporine A (CsA) or other calcineurin inhibitors such as tacrolimus have an 
increased risk of malignancy; conversely, this is generally thought to be due to a decrease 
in tumor immune surveillance101. These clinical findings have led to a large amount of 
Figure 1.4: Simplified diagram of the calcineurin/NFAT 
signaling axis. 
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research ultimately demonstrating that CN/NFAT signaling plays a crucial role not only in 
tumor cells themselves100,102,103 (most likely in an NFAT isoform-specific manner99), but 
in many cell types in the microenvironment as well94. Our lab has previously shown that 
activation of CN/NFAT in the endothelium is a crucial step in the priming of the lung as a 
distant metastatic site104. At the same time, we have shown that genetic deletion of Dscr1 
suppresses tumor growth due to dysregulation of apoptotic ligands and subsequent 
endothelial apoptosis, suggesting that excessive calcineurin signaling can instead limit 
tumor growth (Figure 1.5)105. 
 
 
 
While calcineurin’s role in tumor cells, immune cells, and the endothelium are 
fairly well-characterized, little work has been done to study the effect of CN/NFAT 
specifically in cancer-associated fibroblasts. Previous studies examining the role of 
CN/NFAT in fibroblasts have identified both pro- and anti-fibrotic effects of CN signaling. 
Figure 1.5: The proliferative response to calcineurin 
signaling in endothelial cells follows a U-shaped curve. 
Reproduced from Ryeom et al, Cancer Cell 2008. 
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Long-term treatment of transplant patients with the calcineurin inhibitors cyclosporin A 
(CsA) and/or tacrolimus is often complicated by acute and chronic nephrotoxicity, of which 
tubulointerstitial fibrosis is a hallmark106–108. Further, CsA has been shown to have direct 
fibrogenic effects on renal tubulointerstitial cells and fibroblasts109, and deletion of the a 
isoform of CnA is sufficient to cause renal fibrosis and increased fibronectin and TGFb 
expression in renal fibroblasts110. However, other studies have shown that downregulation 
of CN/NFAT signaling via pharmacologic inhibition or genetic deletion leads to a decrease 
in fibrosis-associated phenotypes in cardiac111,112, dermal113, and lung114 fibroblasts. 
Additionally, many of these studies utilized CsA to inhibit CN, and we and others have 
shown that CsA has a number of calcineurin-independent targets and effects115,116. For 
example, CsA has been shown to attenuate disease progression in a bleomycin model of 
murine lung fibrosis; however, this effect was demonstrated to be independent of 
calcineurin signaling, as administration of tacrolimus did not recapitulate this phenotype117. 
In summary, fibroblast activation is a crucial process in both physiologic and 
pathologic states, but the molecular mechanisms mediating their activation are not fully 
defined, and very little is known regarding the mechanisms maintaining their quiescence. 
There is some previous evidence that CN/NFAT signaling may play a role in fibroblast 
activation, but the current data is conflicting, and results are often confounded by the 
significant off-target effects of pharmacologic inhibition of CN. Therefore, the goal of my 
thesis project was to fully investigate the role of CN/NFAT signaling in fibroblast 
activation in the setting of the lung. By studying the phenotype of the CN-null pulmonary 
fibroblast in vitro and in vivo, we identified how CN specifically mediates the homeostasis 
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and activation of fibroblasts, and how this phenotype may affect disease states such as 
cancer.  
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CHAPTER 2: DELETION OF CALCINEURIN PROMOTES A PRO-
TUMORIGENIC FIBROBLAST PHENOTYPE. 
 
Introduction 
The tumor microenvironment (TME) consists of multiple cell types, including 
endothelial, immune, and stromal cells118. It is instrumental in the development of both 
primary tumors and distant metastases, making it an appealing potential therapeutic target. 
Fibroblasts, a key component of the stroma, are cells of mesenchymal origin that play a 
number of roles in both normal and diseased tissues. Resident fibroblasts can orchestrate 
and maintain the architecture of extracellular matrix (ECM) in normal tissues, but 
activation of fibroblasts is crucial to dynamically remodel the matrix in both physiologic 
processes such as wound healing as well as pathologic processes such as fibrosis and 
cancer119. Studies have indicated that normal tissues are resistant to tumor cell colonization 
and growth due in part to fibroblast homeostasis, and that fibroblast activation is required 
for both primary tumor progression and metastatic colonization119,120. While multiple 
stimuli that contribute to the activation of fibroblasts have been identified, the cell-intrinsic 
molecular mechanisms underlying the transition from quiescent to activated fibroblasts, or 
the “stromagenic switch,” are less well understood.  
The most widely used markers of activated fibroblasts currently include fibroblast 
activation protein (FAP)121,122 and the myofibroblast marker alpha-smooth muscle actin 
(aSMA)123. Expression of these and other markers indicate they represent heterogeneous 
populations with unique gene expression profiles dependent on both context and tissue of 
origin124. However, collectively, activated fibroblasts can increase their migration and 
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contractility, secrete and remodel extracellular matrix, including collagen, and produce 
cytokines and growth factors that affect other cellular compartments in the 
microenvironment such as the immune system and the endothelium. A variety of stimuli 
are responsible for fibroblast activation, including changes in substratum mechanical 
stiffness, composition and architecture of the ECM, growth factors such as TGFb or PDGF, 
cytokines and chemokines, and sources of cellular stress such as hypoxia or ROS125. 
 While many of the activating stimuli of fibroblasts and their downstream mediators 
of activation have been well-defined, less is known about cell-intrinsic pathways required 
to maintain the homeostatic state of resident un-activated fibroblasts. It is increasingly 
evident that quiescence is not simply a default state but rather requires active maintenance; 
however, little is known about the intracellular signaling pathways responsible for 
maintaining homeostasis71. The calcineurin (CN)/nuclear factor of activated T cells 
(NFAT) signaling pathway was originally identified as critical for T cell activation and has 
since been shown by us and others to also play key roles in numerous other cell types, 
including endothelial cell activation and tumor angiogenesis95,104,105. CN is a calcium-
regulated serine-threonine phosphatase that consists of two subunits: a catalytic 
(calcineurin A) and a regulatory subunit (calcineurin B)93. Upon increased calcium flux 
into the cytoplasm, calcineurin is activated through a conformational change, exposing its 
catalytic site. Its best-known substrates are the NFAT family of transcription factors, which 
translocate to the nucleus upon their dephosphorylation by CN and transactivate tissue-
specific genes. We previously demonstrated that the CN/NFAT pathway plays a key role 
in mediating endothelial cell activation downstream of VEGF, and that pharmacologic or 
genetic deregulation of CN signaling affects both primary tumor growth and metastatic 
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progression95,104,105. Prior studies by others have shown contrasting effects of the CN 
pathway in activated fibroblasts, with reports of both pro- and anti-fibrotic effects of CN 
in vitro and in vivo37-45. Moreover, to our knowledge, the role of CN/NFAT in fibroblasts 
in the TME has not yet been investigated.  
As the CN/NFAT pathway has been implicated in regulating the function of 
multiple cell types in the TME94, as well as in fibroblast activation in wound healing and 
fibrosis, we hypothesized that CN/NFAT may play a role in regulating the function of 
fibroblasts in the TME. To test this hypothesis, we examined the role of CN signaling in 
lung fibroblasts and assessed the impact of fibroblast-specific deletion of CN on lung 
metastasis. Here we demonstrate that acute deletion of calcineurin in lung fibroblasts leads 
to increased proliferation, migration, and contractility compared to wild-type fibroblasts, 
changes consistent with activation. Furthermore, we found that extracellular matrix derived 
from Cn-/- fibroblasts contains greater amounts and more linearly aligned fibrillar collagen, 
and that Cn-/- fibroblasts support more robust endothelial cell tube formation in vitro. 
Consistent with our in vitro findings, we found that stromal cell specific Cn deletion in 
mice leads to a higher incidence and increased size of lung metastases in a spontaneous 
lung metastasis model with two different tumor cell lines. Our findings implicate CN in 
maintaining fibroblast homeostasis in normal, unstimulated states, and in attenuating the 
pro-tumorigenic activity of fibroblasts in the metastatic niche.  
 
Results 
Calcineurin deletion in vitro promotes fibroblast migration  
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       To analyze the role of calcineurin in fibroblast activation in vitro, we treated 
primary lung fibroblasts derived from calcineurin B (CnB) floxed mice with adenoviral 
Cre recombinase. Deletion of CnB destabilizes and promotes proteolytic degradation of the 
calcineurin A subunit126. Benign and malignant diseases, including wound healing, 
fibrosis, and cancer, all feature increased numbers of fibroblasts that can be attributed to a 
combination of fibroblast proliferation, migration of nearby resident fibroblasts to lesions, 
and recruitment of mesenchymal precursors from the bone marrow. Thus, we first 
examined whether acute deletion of CN altered fibroblast proliferation. We observed no 
difference in cell proliferation between WT and Cn-/- fibroblasts (Figure 2.1A). However, 
in scratch assays of confluent monolayers, Cn-/- fibroblasts exhibited enhanced closure at 
24 hours post-wounding (Figure 2.1B), and live-cell imaging over the first 24 hours post-
scratch revealed that Cn-/- fibroblasts exhibited accelerated and markedly different 
migratory phenotypes compared to WT fibroblasts. Specifically, Cn-/- fibroblasts migrated 
oriented perpendicularly to the leading edge of the wound as compared to WT fibroblasts, 
which exhibited more stochastic motion throughout wound closure (Supplemental Video 
1).  
      The accelerated wound closure by Cn-/- fibroblasts in scratch assays suggested that 
deletion of calcineurin might increase the migratory ability of fibroblasts. Indeed, we found 
that in uncoated transwell migration assays, Cn-/- fibroblasts exhibited greater migration 
compared to wild-type fibroblasts after 24 hours (Figure 2.1C). However, Cn-/- fibroblasts 
exhibited impaired migration compared to WT controls on transwells coated with type I 
collagen (Figure 2.1D), implicating an inability of calcineurin-null fibroblasts to invade 
and migrate through a collagen matrix. Collectively, these data indicate that while CN 
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deletion increased fibroblast migration, it inhibited collagen invasion and had no effect on 
fibroblast proliferation.  
 
 
Calcineurin-null fibroblasts exhibit increased collagen contractility and matrix 
remodeling   
      As another key function of activated fibroblasts is to process and remodel collagen, 
we plated fibroblasts onto thick type I collagen gels. In the absence of fibroblasts, these 
collagen gels contain very little fibrillar collagen as visualized by 2-photon second 
harmonic generation (SHG) imaging; once fibroblasts are added, they remodel and exert 
  
FIGURES 
 
Figure 1.1: Calcineurin deletion promotes fibroblast migration but inhibits invasion. A.  WT 
and Cn-/- lung fibroblasts were counted on the indicated days after plating in normal growth media, 
and proliferation was assayed by EdU uptake (24 hour pulse). Cell counts are pooled from 2 
separate experiments. B. Representative images from scratch assay at indicated time after scratch. 
Red dotted lines: width of scratch at 0 hour time point. Scratch closure rate was calculated using 
the change in scratch area over time for 18 images (N=9 each WT and Cn-/-). Magnification bar = 
250 µm. N=4 experimental replicates. C. Representative images and quantification of transwell 
migration assays. WT or Cn-/- fibroblasts were plated in serum-free media in the upper chamber of 
transwells and migrated toward serum-containing media in lower chamber. Migration was 
assessed after 24 hours by staining with crystal violet. D. Fibroblast invasion assays on transwells 
coated with type I rat tail collagen demonstrate decreased migration toward serum-containing 
media by Cn-/- fibroblasts after 18 hours. C,D bar = 500 µm. All samples were performed in 
triplicate; N=3 for migration, N=2 for collagen invasion. *p<0.05, **p<0.01. Error bars = standard 
deviation. 
  
Figure 1: Calcineurin deletion promotes fibroblast migration but 
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Figure 2.1: Calcineurin deletion pro otes fibroblast igration but inhibits invasion. A.  WT 
and Cn-/- lung fibroblasts were counted on the indicated days after plating in normal growth media, 
and proliferation was assayed by EdU uptake (24 hour pulse). Cell counts are pooled from 2 separate 
experiments. B. Representative images from scratch assay at indicated time after scratch. Red dotted 
lines: width of scratch at 0 hour time point. Scratch closure rate was calculated using the change in 
scratch area over time for 18 images (N=9 each WT and Cn-/-). Magnification bar = 250 µm. N=4 
experimental replicates. C. Representative images and quantification of transwell migration assays. 
WT or Cn-/- fibroblasts were plated in serum-free media in the upper chamber of transwells and 
migrated toward serum-containing media in lower chamber. Migration was assessed after 24 hours 
by staining with crystal violet. D. Fibroblast invasion assays on transwells coated with type I rat tail 
collagen demonstrate decreased migration toward serum-containing media by Cn-/- fibroblasts after 
18 hours. C,D bar = 500 µm. All samples were performed in triplicate; N=3 for migration, N=2 for 
collagen invasion. *p<0.05, **p<0.01. Error bars = standard deviation. 
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tension on the collagen substratum, leading to the formation of a network of collagen fibers 
visible by SHG. Cn-/- fibroblasts remodeled type I collagen gels to a greater extent than WT 
fibroblasts, leading to increased SHG signal (Figure 2.2A).  
      To further investigate the effects of CN deletion on collagen remodeling, we 
utilized a collagen contraction assay, in which fibroblasts were embedded in a type I 
collagen gel that was then detached and allowed to float freely in culture medium. When 
the solidified collagen gels are detached, a combination of collagen remodeling and 
fibroblast contractility exerts forces on the gel, causing it to contract127. CN deletion 
significantly increased the rate of collagen gel contraction at 6 and 12 hours post-
detachment with maximal contraction by 12 hours. In contrast, WT fibroblasts required 
almost 20 hours post-detachment for maximal contraction (Figure 2.2B).  
      We assessed the ability of Cn-/- fibroblasts to deposit, accumulate and remodel 
collagen by comparing fibroblast-derived matrices (FDMs) from WT and Cn-/- fibroblasts 
128. We found that CN deletion led to significant increases in the accumulation of fibrillar 
collagen and alignment of collagen fibrils as observed by SHG imaging (Figure 2.2C). 
Extracellular matrix can be remodeled through multiple mechanisms, including the 
production of collagenases by fibroblasts, so we compared the collagenase activity 
associated with CN-null and WT fibroblasts by overlaying DQTM type I collagen on 
fibroblasts cultured on collagen gels. DQ collagen is saturated with quenched fluorescein 
molecules, and digestion by collagenases releases fluorescent fragments of collagen that 
are visible by fluorescence microscopy. Cn-/- fibroblasts plated on either gelatin-coated 
chamber slides or a collagen substratum exhibited greater collagenase activity than WT 
fibroblasts (Figure 2.2D-E).  
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Figure 2: Calcineurin-null fibroblasts exhibit increased collagen 
contractility and matrix remodeling.
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Figure 2.2: Calcineurin-null fibroblasts exhibit increased collagen contractility and matrix 
remodeling. A. Phase-contrast and 2-photon second harmonic generation (2P-SHG) images of WT and 
Cn-/- fibroblasts cultured on collagen gels in serum-containing media for 48 hours. Total SHG signal 
(green) was quantified using ImageJ and normalized to cell count as measured by autofluorescent signal 
(white). Magnification bar = 250 µm. B. Representative images (after 6 hours) and quantification of 
collagen contraction by WT and Cn-/- fibroblasts at indicated times. White dotted lines denote collagen 
gel circumference. C. Representative 2P-SHG images of fibroblast-derived matrices. Total SHG signal 
(green) was quantified using ImageJ, and collagen fiber alignment scores were determined using 
CurveAlign software. Bar = 100 µm. D. Images from DQ collagen assay on gelatin-coated glass and 
quantification of average DQ signal per nucleus using ImageJ. E. Images from DQ collagen assay on 
type I collagen gels. Collagenase-digested DQTM collagen signal is green and nuclei (DAPI stain) are 
blue. Bar = 250 µm.  All samples were assayed in triplicate, N=2-5. *p<0.05, **p<0.01. Error bars = 
standard deviation. 
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This effect was specific for collagenase activity, as we observed no difference in gelatinase 
activity under either culture condition (data not shown). Taken together, our data indicate 
that CN deletion leads to an increase in collagen accumulation, remodeling, and 
contractility in the absence of exogenous activating stimuli, suggesting that the calcineurin 
pathway may be important for fibroblast homeostasis. 
 
Calcineurin deletion leads to alterations in collagen processing consistent with a CAF-like 
state 
      Given that higher fiber density and greater fiber alignment are characteristic of 
FDMs derived from cancer-associated fibroblasts, we compared WT and Cn-/- fibroblast-
derived matrices generated in the presence of normal media or cancer cell conditioned 
media (CM) from SR0144 cells, a murine lung adenocarcinoma cell line driven by loss of 
Tp53 and expression of oncogenic Kras. As expected, when WT fibroblasts were cultured 
with tumor CM, we observed a greater accumulation of fibrillar collagen in the generated 
matrix as measured by SHG signal than in matrix generated by WT cells in normal media.  
We also observed foci of more highly aligned collagen in FDMs generated by WT cells in 
the presence of tumor CM. Interestingly, we found that FDMs generated by Cn-/- fibroblasts 
in the presence of normal media also exhibited increased accumulation of fibrillar collagen 
similar to that seen in WT FDMs generated in tumor CM (Figure 2.3A). These data suggest 
Cn-/- fibroblasts are phenotypically similar to tumor cell CM-treated WT fibroblasts and do 
not respond to further stimulation by tumor CM. 
2 
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      We decellularized and examined Cn-/- and WT FDMs at earlier timepoints to 
determine differences in matrix deposition and remodeling. After 3 days, there were 
noticeable differences in both fibroblast and matrix alignment in CN-null fibroblasts as 
determined by phase contrast imaging, which were further enhanced after 5 days (Figure 
2.3B). Consistent with the increase in linear alignment of collagen fibrils in FDMs derived 
from Cn-/- fibroblasts, the cells themselves were also more linearly aligned and elongated.  
 
 
 
  
 
 
Figure 1.3: Calcineurin deletion leads to alterations in collagen processing consistent with a 
CAF-like state. A. SHG images of WT or Cn-/ fibroblast-derived matrices (FDMs) with and 
without lung tumor conditioned media. Total SHG signal (in green) was measured using ImageJ, 
and collagen fiber alignment scores were determined using CurveAlign software. Bar=100 µm. B. 
Phase-contrast images of WT and Cn-/- fibroblasts and fibroblast-derived matrices (FDMs) 
following 3 and 5 days of ascorbate treatment. Bar = 100 µm. N=2-3 (3-5 fields per FDM imaged), 
*p<0.05. Error bar = standard deviation. 
  
Figure 3: Calcineurin deletion leads to alterations in collagen 
processing consistent with a CAF-like state. 
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Figure 2.3: Calcineurin deletion leads to alterations in collagen processing consistent with a 
CAF-like state. A. SHG images of WT or Cn-/ fibroblast-derived matrices (FDMs) with and 
without lung tumor conditioned media. Total SHG signal (in green) was measured using ImageJ, 
and collagen fiber alignment scores were determined using CurveAlign software. Bar=100 µm. B. 
Phase-contrast images of WT and Cn-/- fibroblasts and fibroblast-derived matrices (FDMs) 
following 3 and 5 days of ascorbate treatment. Bar = 100 µm. N=2-3 (3-5 fields per FDM imaged), 
*p<0.05. Error bar = standard deviation. 
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Cytoskeletal reorganization in fibroblasts is regulated by calcineurin 
      Our data show that calcineurin regulates fibroblast-mediated matrix remodeling, 
and it is well-established that alterations in matrix organization drive cytoskeletal 
reorganization as well as cell size and shape. Thus, we compared how FDMs derived from 
WT and CN-deleted fibroblasts affected reorganization of the actin cytoskeleton in 
fibroblasts and/or tumor cells. When WT fibroblasts were plated on Cn-/- FDMs and stained 
for phalloidin and the focal adhesion complex protein paxillin, they extended long, thin 
cytoplasmic processes and demonstrated an elongated morphology compared to their 
behavior on WT FDMs (Figure 2.4A). We also plated murine YFP-expressing pancreatic 
ductal adenocarcinoma cells (PDAC) onto FDMs generated from WT and Cn-/- fibroblasts 
and analyzed their cytoskeletal architecture via phalloidin staining and confocal 
microscopy. Similar to the fibroblasts, PDACs cultured on FDMs derived from Cn-/- 
fibroblasts were also elongated (Figure 2.4B), and live-cell imaging of PDACs on these 
FDMs revealed greater displacement and more linear movement on Cn-/- FDMs as 
compared to WT FDMs (Figure 2.4C-D, Supplemental Video 2). Therefore, the matrix 
generated by Cn-/- fibroblasts is sufficient to significantly alter the cytoskeletal architecture 
of both tumor cells and fibroblasts as compared to matrix derived from WT fibroblasts.  
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Figure 4: Calcineurin-null fibroblast-derived matrices induce 
cytoskeletal reorganization. 
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Figure 2.4: Calcineurin-null fibroblast-derived matrices induce cytoskeletal reorganization. A. 
Confocal images of WT fibroblasts cultured on WT or Cn-/- fibroblast-derived matrix (FDM) and stained 
with paxillin (red), phalloidin (green), and DAPI (blue). Aspect ratio was calculated by dividing the 
width by the length for each cell. Bar = 50 µm. B. Confocal images of MH6449 PDAC cells cultured on 
WT or Cn-/- FDMs and stained with phalloidin (green) and DAPI (blue). Bar = 50 µm. Assay was 
performed in triplicate. ***p<0.001, ****p<0.0001. C. Representative live-cell tracking images of 
PDACs on WT or Cn-/- FDMs with magnified representative area denoted by dotted yellow box. Each 
line is an individual cell’s path over 24 hours. Bar = 200 µm. D. Quantification of mean square 
displacement and straightness of cell track. Each data point represents the average value from all cell 
tracks in 1 image. Assay was performed in duplicate, values pooled from N=6 images/videos per 
replicate. Error bar = standard deviation. 
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Loss of calcineurin in fibroblasts promotes EC tube formation 
      Activated fibroblasts and their associated matrix play a crucial role in angiogenesis, 
both by providing structural support and by secreting pro-angiogenic factors. We utilized 
a co-culture model of EC tube formation in which primary lung ECs were mixed with WT 
or Cn-/- fibroblasts on basement membrane extract (BME), and 2D tube formation was 
quantified. Cn-/- fibroblasts supported more robust EC tube formation measured by number 
of tube segments and branch points as compared to WT fibroblasts (Figure 2.5A).  
      Therefore, we examined the secretome of WT and Cn-/- fibroblasts during tube 
formation. We generated conditioned media from WT and Cn-/- fibroblasts cultured on 
BME and probed for angiogenesis-related proteins. Deletion of CN led to significant 
upregulation of multiple cytokines and growth factors, including SDF-1, a chemokine that 
has been shown to promote angiogenesis as well as the myofibroblast phenotype in both 
cancer and fibrotic disease129–132 (Figure 2.5B). Thus, the differences observed in our in 
vitro tubulogenesis assays may be at least partially mediated by differences in angiogenic 
secreted factors of CN-null fibroblasts.  
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Loss of calcineurin in fibroblasts promotes metastasis 
      Our data suggest that CN deletion in fibroblasts leads to an activated phenotype in 
fibroblasts that may be pro-tumorigenic. To investigate tumor growth and metastases in 
mice with fibroblast specific deletion of calcineurin, we cross-bred calcineurin B floxed 
mice with transgenic mice expressing tamoxifen-inducible Cre driven by a fragment of the 
type I collagen alpha-1 chain promoter (Col1a1-Cre-ER(T))133,134 to delete CN from the 
stroma in vivo. While previous literature suggested that the 2.3kb fragment of the Col1a1 
  
 
 
Figure 1.5: Cn-/- fibroblasts promote endothelial cell tube formation. A. Representative images 
from tube formation assay with WT vs Cn-/- fibroblast + GFP+ endothelial cell (EC, green) co-
cultures embedded in basement membrane extract (BME) at 24h following plating. Images are 
from 1 representative experiment (N=2 images from 1 replicate for quantification) of 6 
experimental replicates. Quantification was performed on phase images using the Angiogenesis 
Analyzer tool in ImageJ. B. Conditioned media from WT or Cn-/- fibroblasts cultured on BME for 
24 hours was analyzed with an angiogenesis antibody array. Cytokines with statistically significant 
differences between WT and Cn-/- fibroblasts (p<0.05) are quantified on right. **p<0.01, 
***p<0.001. N=2 per condition; array contained technical duplicates for each cytokine. Error bar 
= standard deviation. 
  
Figure 5: Cn-/- fibroblasts promote angiogenesis.
A
B WTCn-/-
No
rm
al
iz
ed
 d
en
si
ty
WT Cn-/-
GFP EC alone + WT fibroblast + Cn-/- fibroblast
Ph
as
e
G
FP
24
 h
Segments Branch
points
Figure 2.5: Cn-/- fibroblasts promote endothelial cell tube formation. A. Representative images 
from tube formation assay with WT vs Cn-/- fibroblast + GFP+ endothelial cell (EC, green) co-cultures 
embedded in basement membrane extract (BME) at 24h following plating. Images are from 1 
representative experiment (N=2 images from 1 replicate for quantification) of 6 experimental 
replicates. Quantification was performed on phase images using the Angiogenesis Analyzer tool in 
ImageJ. B. Con itioned m dia from WT or Cn-/- fibroblasts cultured on BME for 24 hours was 
analyzed with an angiogenesis antibody array. Cytokines with statistically significant differences 
between WT and Cn-/- fibroblasts (p<0.05) are quantified on right. **p<0.01, ***p<0.001. N=2 per 
condition; arr y contained techn cal duplic tes for each cytokine. Error bar = standard deviation. 
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promoter is solely expressed in dermal fibroblasts (along with osteoblasts and 
osteoclasts),we demonstrated Cre expression as well as a significant decrease in CN 
expression in lung fibroblasts after 1 week of tamoxifen administration (Figure 2.6A).   
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Figure 6: Stromal calcineurin deletion increases the 
incidence and size of lung metastases.
DC Tumor
resection
LLC/PDAC
injection
Stromal CN
deletion
Analysis
14d500 mm35d
4/7 2/6
7/7 4/6
Time (days)
Vo
lu
m
e 
(m
m
3 )
CnBfl/fl
Col1a2-Cre;
CnBfl/fl
E
# 
lu
ng
 m
et
s/
m
ou
se
LLC PDAC
N
or
m
al
iz
ed
 m
et
 s
iz
e
LLC PDAC
CnBfl/fl
Col1a1-Cre; CnBfl/fl
A
+Col1a1-Cre
N
or
m
al
iz
ed
 C
nA
-
B
+-
R
el
at
iv
e 
ex
pr
es
si
on
Col1a1-Cre
CnBfl/fl +Col1a1-Cre
CnA
Actin
Figure 2.6: Stromal deletion of calcineurin increases the incidence and size of lung metastases. 
A. Confirmation of stromal Cn knockdown in lung fibroblasts from Col1a1-Cre-ER(T);CnBfl/fl mice 
by Western blot for CnA. B. qPCR for Col1a1-Cre. Each lane represents lung fibroblasts isolated from 
1 mouse. C. Schematic of injection-resection spontaneous metastasis experiments in CnBfl/fl (WT) and 
Col1a1-Cre-ER(T);CnBfl/fl (KO) mice. d, day. D. Volume of PDAC flank tumors on the indicated days 
prior to resection in the injection-resection experiment. E. Quantification of lung metastases (mets) 
per mouse and average size of lung mets. Size of lung mets was normalized to total lung area. N=13 
(6 WT, 7 KO) each for LLC and PDAC experiments. F. Representative H&E images from PDAC and 
LLC lung metastases with fraction of metastasis-bearing mice indicated. Bar = 500 µm. Each slide 
represents all lung lobes from a single mouse. Error bar = standard deviation. 
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       To examine both primary tumor growth and metastases, we utilized an injection-
resection experimental model of spontaneous lung metastasis using two separate tumor cell 
lines: Lewis lung carcinoma and the MH6449 PDAC cell line. Following tamoxifen 
injection to delete CN from fibroblasts, subcutaneous tumors were established and allowed 
to grow to 400-600 mm3 before resection; 14 days following resection, mice were 
sacrificed and lungs analyzed for metastases (Figure 2.6B). There was no significant 
difference in primary tumor growth between Cnfl/fl (WT) and Col1a1-Cre;CnD/D  mice 
(Figure 2.6C). However, there was an increase in the size of LLC lung mets and a trend 
towards larger PDAC lung metastases in Col1a1-Cre;CnD/D  mice (Figure 2.6D). 
Additionally, 6/6 of stromal Cn D/D  vs 4/6 WT mice in the LLC and 4/6 vs 2/6 in the PDAC 
model developed visible lung metastases, indicating an increase in the development of lung 
metastases upon CN deletion in lung fibroblasts (Figure 2.6E). These data suggest that 
stromal deletion of CN specifically increases both the colonization and outgrowth of lung 
metastases.  
Expression of constitutively active NFAT signaling partially rescues CN deletion  
 To determine whether restoration of NFAT activation could rescue the phenotype 
of Cn-/- fibroblasts and limit fibroblast activation, we transduced Cn-/- fibroblasts with a 
constitutively nuclear form of NFATc1 (caNFATc1) (Figure 2.7A) and assayed its effects 
on collagen remodeling and migration. Expression of caNFATc1 partially reversed the 
increase in collagenase activity of Cn-/- fibroblasts in DQ type I collagen assays as 
compared to Cn-/- fibroblasts (Figure 2.7B). However, scratch assays on Cn-/- fibroblasts 
with caNFATc1 expression showed similar increased migration and a flattened fibroblast 
morphology similar to Cn-/- fibroblasts (Figure 2.7D) and had a nominal effect on fibrillar 
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collagen remodeling in fibroblasts cultured on type I collagen gels (Figure 2.7C). These 
data suggest that restoration of NFAT signaling leads to a decrease in collagenase activity 
by CN-null fibroblasts similar to WT fibroblasts but does not significantly affect fibroblast 
migration and fibrillar collagen remodeling. 
 
Discussion 
In this study, we characterized the effect of CN deletion in fibroblasts in vitro and 
in vivo. Our data show that calcineurin deletion in fibroblasts in vitro leads to a number of 
functional alterations consistent with an activated, pro-tumorigenic fibroblast phenotype. 
This suggests CN may play a crucial role in the maintenance of fibroblast homeostasis or 
the “un-activated” state. We demonstrate that Cn-/- fibroblasts exhibited greater migratory 
capacity during scratch assays and transwell migration assays; however, they do not invade 
Figure 2.7: Constitutively active NFAT partially rescues CN deletion. A. P3 Cn-/- fibroblasts 
treated with pMX-puro or pMX-caNFATc1 were cultured in 10% FBS containing media overnight 
before being stained for NFATc1 localization (red). Each condition was performed in duplicate. Bar = 
100 µm. B. DQ collagen was incubated for 24 hours with Cn-/- fibroblasts treated with pMX-puro or 
pMX-caNFATc1 on gelatin-coated glass chamber slides. Bar = 100 µm. C. Cn-/- fibroblasts were 
plated on thick 1mg/ml collagen gels for 48 hours, and collagen fibrils were imaged using 2P-SHG. 5 
images taken per plate. Green = SHG; white = autofluorescent cells. Bar = 100 µm. D. Cn-/- fibroblast 
treated with pMX-puro or pMX-caNFATc1 were wounded with a pipet tip, and migration in 10% 
serum-containing media was measured. Red dotted lines denote original width of scratch. Bar = 250 
µm. N=2-3 technical replicates per experiment, N=1 experimental replicate. 
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through type I collagen gels to the same extent as WT. Our studies identified a role for CN 
in the deposition and remodeling of extracellular matrix, particularly collagen, with Cn-/- 
fibroblasts exhibiting increased collagenase activity and collagen remodeling. CN deletion 
leads to an increase in fibrillar collagen in Cn-/- fibroblast-derived matrices and when Cn-/- 
fibroblasts are cultured on type I collagen gels. These differences in matrix direct the 
cytoskeletal reorganization of both fibroblasts and tumor cells, and tumor cells exhibit 
more linearly directed movement when cultured on Cn-/- matrix. Finally, our in vitro studies 
show that CN-null fibroblasts promote endothelial cell tube formation and increase their 
production of angiogenesis-related proteins. Fibroblast-specific deletion of CN in vivo 
increased the incidence and size of lung metastases in an experimental model of 
spontaneous metastasis. Our data suggest that CN deletion leads to an activated fibroblast 
phenotype in the absence of activating stimuli, phenocopying cancer-associated, pro-
tumorigenic fibroblasts. 
We show that CN deletion leads to an increase in fibroblast migratory capacity, but 
a decrease in invasion through type I collagen. Given that Cn-/- fibroblasts demonstrated 
increased collagenase activity in other assays, it is unlikely that this phenotype is caused 
by a decrease in collagen proteolysis. It is possible that the increased collagenase activity 
as observed in the DQ collagen assays revealed a greater number of cryptic binding sites 
to which the Cn-/- fibroblasts can bind via engagement of their integrins, or that the increase 
in fibrillar collagen as observed by SHG imaging of Cn-/- fibroblasts on type I collagen gels 
encouraged engagement of integrins with specificity for collagen in its triple helical fibril 
structure, such as integrins a1b1 and a2b150. This pro-remodeling phenotype may promote 
interactivity with the collagen substratum instead of invasion through it.  
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    Our work also identifies a role for CN in the secretion and remodeling of 
extracellular matrix, specifically in collagen. Cn-/- fibroblasts are capable of both 
remodeling and exerting contractile forces on existing collagen substrates as well as 
secreting and remodeling new ECM de novo to a greater extent than WT fibroblasts. 
However, we observed no difference in gelatinase activity, suggesting that calcineurin 
specifically regulates the processing of fibrillar collagen and not its denatured form, 
possibly through differential expression of collagenases but not gelatinases. Fibroblast-
derived matrices generated using Cn-/- fibroblasts have a greater amount of fibrillar 
collagen that is more linearly aligned, findings that are consistent with FDMs generated 
from cancer-associated fibroblasts compared to normal fibroblasts135. In support of this 
hypothesis, WT FDMs generated in the presence of tumor-conditioned media resemble Cn-
/- FDMs generated in normal growth media, and Cn-/- FDMs do not undergo further changes 
when generated in the presence of tumor-conditioned media.  
We then demonstrated that the matrix derived from Cn-/- fibroblasts is sufficient to 
direct the cytoskeletal architecture of both WT fibroblasts and PDAC tumor cells, causing 
their aspect ratio to increase. The elongation of PDACs on Cn-/- FDMs as measured by cell 
aspect ratio may be an indicator that these cells are undergoing epithelial-to-mesenchymal 
transition (EMT) at a higher rate than PDACs cultured on WT FDMs. The increased 
straightness of tumor cell migration paths on Cn-/- FDMs, as well as the right-skewing of 
the mean square displacement distribution of PDACs on Cn-/- FDMs, corresponds to their 
increased migration along the more linearly aligned collagen fibrils, a phenomenon that is 
frequently observed in tumor growth and invasion in vivo136. 
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We propose that the alterations in collagen fiber architecture we observed in vitro 
may inform the increase in the incidence and size of metastases in stromal CN-null mice 
in an experimental model of spontaneous metastasis. We did not observe gross differences 
in collagen fiber morphology or density, or in microvessel density in the PDAC primary 
tumors from the injection-resection experiments (data not shown); however, at the time of 
resection, these tumors were very large (~500 mm3), well past the size at which the 
angiogenic and stromagenic switch occur7,119. It may be that differences in ECM 
architecture and angiogenesis at earlier time points may enhance the intravasation of tumor 
cells, and analyzing tumors at the time of resection masks any differences that may be more 
apparent earlier, despite no difference in the rate of primary tumor growth. 
 Our work identifies calcineurin as one of the necessary signaling pathways through 
which fibroblast homeostasis is regulated, as deletion of calcineurin leads to activation in 
the absence of exogenous activating stimuli such as TGF-b. While our work is the first to 
identify a role for CN specifically in fibroblast homeostasis, CN deletion has been shown 
to disrupt homeostasis in many other cell types and disease models137–140. The current 
literature examining the role of CN/NFAT signaling in fibroblast activation, however, is 
complex. Evidence exists for both pro- and anti-fibrotic effects of CN/NFAT signaling in 
fibroblasts isolated from a variety of tissues106–114. However, it is important to note that 
some of this work was conducted using pharmacologic inhibition of CN via CsA; we and 
others have shown that CsA has a significant number of calcineurin-independent targets 
and effects115,116, and the anti-fibrotic effects of CsA observed in one study were not 
recapitulated when tacrolimus, a CN inhibitor with a different mechanism of action, was 
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utilized117. Therefore, it is possible that many of the anti-fibrotic effects of CsA 
administration that have been previously observed are due to its off-target effects.  
We must consider whether the activated phenotype of Cn-/- fibroblasts is dependent 
on NFAT signaling, as CN has been shown to dephosphorylate a number of other targets 
outside of NFAT93,141. Previous evidence suggests that NFAT is activated in response to 
activating stimuli such as mechanical stretching or TGF-b treatment111,142; however, 
constitutively active NFAT can instead suppress myofibroblast transdifferentiation143. One 
possible NFAT target that may be at least partially responsible for the phenotype we 
observed is SDF-1/CXCL12, a pro-fibrotic and pro-angiogenic chemokine that was 
upregulated in Cn-/- fibroblasts in our angiogenic secretome array as well as in 
cytokine/chemokine secretome arrays generated from fibroblasts cultured on both type I 
collagen gels and fibronectin-coated hydrogels (data not shown). Some evidence exists for 
the negative regulation of SDF-1 by NFAT in osteoblasts144 and cytotrophoblast cells145. 
Thus, one potential mechanism by which calcineurin deletion leads to a pro-tumorigenic 
phenotype in fibroblasts may be via this increase in autocrine SDF-1 expression.  
Collectively, our data demonstrate a role for calcineurin signaling in fibroblast 
homeostasis by showing that calcineurin deletion leads to a pro-tumorigenic, activated 
phenotype in primary lung fibroblasts, and that stromal deletion of CN in vivo leads to an 
increase in the incidence and size of lung metastases. Though the increased incidence of 
tumors in transplant patients receiving calcineurin inhibitors has often been attributed to 
the desired immune suppressive effects of these drugs, our work demonstrates that the 
effects of calcineurin inhibition on the stroma may also a play a part in this phenomenon. 
Further elucidation of the specific transcriptional targets of NFAT in lung fibroblasts may 
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identify specific signaling cascades through which this homeostasis is maintained as well 
as potential pathways to pharmacologically target the stroma. 
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CHAPTER 3: CALCINEURIN-NULL FIBROBLASTS DO NOT RESPOND TO 
TGF-b STIMULATION IN VITRO. 
 
Introduction 
 We have shown in Chapter 2 that deletion of calcineurin in primary lung 
fibroblasts leads to an activated, pro-tumorigenic phenotype in the absence of exogenous 
activating stimuli. Next, we wished to determine how Cn-/- fibroblasts would respond when 
activating stimuli were added. Previously, we showed that the content and alignment of 
WT fibroblast derived matrices are significantly altered upon the addition of tumor 
conditioned media, whereas Cn-/- FDMs are not. This suggests that despite their baseline 
activation, Cn-/- fibroblasts may be unable to respond to certain activating stimuli to the 
same extent as WT. TGF-b1 is one of the main cytokines responsible for fibroblast 
activation in wound healing, fibrotic disease, and cancer; thus, we elected to specifically 
investigate the role of CN signaling in the functional response to TGF-b stimulation in 
fibroblasts.  
 The TGF-b superfamily of growth factors consists of a large group of proteins that 
are similar in their dimeric protein structure, often featuring disulfide bonding between the 
two monomers146. They can be divided into several subgroups: the transforming growth 
factors (TGF), bone morphogenic proteins (BMP), activins and inhibins, growth 
differentiation factors (GDF), and other factors such as Müllerian inhibiting substance 
(MIS). TGF family members are only expressed in vertebrates and play a significant role 
in normal development. Additionally, dysregulation of TGF signaling is implicated in a 
variety of disease states146: many tumor cells secrete increased levels of TGF-b1, leading 
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to widespread inflammatory and pro-fibrotic changes, and TGF-b1 is often implicated as 
one of the major inflammatory cytokines responsible for fibrotic disease147. 
Given its important role in many developmental and physiologic processes, TGF 
signaling is a highly regulated and controlled process. TGF-b is initially secreted in a latent, 
inactive form; an N-terminal latency-associated protein (LAP) is disulfide bonded to the 
active C-terminal TGF domain, and this bond must be disrupted in order for active TGF-b 
to be released148.  Active TGF-b binds the TGF-b receptor, a heterodimer consisting of one 
type I and one type II receptor; these heterodimers themselves dimerize, forming an active 
intracellular kinase complex147. The canonical TGF-b signaling pathway following 
engagement and dimerization of the TGF-b receptor occurs when the dimerized TGF-b 
receptor phosphorylates regulatory Smad (R-Smad) proteins such as Smad2 and Smad3. 
These R-Smads form heterodimers with Smad4, and this heterodimer translocates to the 
nucleus and regulates the expression of a wide variety of genes. Control of TGF-b signaling 
is mediated by a variety of endogenous inhibitory factors. The expression of inhibitory 
Smads (I-Smads) is stimulated by TGF-b signaling, thus forming a negative feedback loop. 
The effects of TGF stimulation are often concentration-dependent, with opposing effects 
on cellular function and gene expression at low versus high concentrations of TGF149–151. 
In many cell types, such as podocytes, TGF-b signaling is pro-proliferative at low 
concentrations and becomes pro-apoptotic above a critical threshold concentration, often 
in a Smad3-dependent manner152. 
 TGF-b signaling also varies significantly based on cellular context, as evidenced 
by the many often contradictory roles TGF-b plays in different cell types and disease 
settings153. Specifically, in fibroblasts, TGF-b1 signaling has been associated with 
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differentiation into the myofibroblast phenotype in wound healing, fibrosis, and cancer. 
TGF-b stimulation of fibroblasts leads to the upregulation of a number of pro-fibrotic 
genes, including ECM proteins such as the a-1 chain of type I collagen (COL1A1) and the 
EDA variant of fibronectin (EDA-FN), matrix metalloproteinases (MMPs), and other 
collagen remodeling enzymes such as lysyl oxidase (LOX). It also directly regulates the 
expression of the myofibroblast marker aSMA and can lead to an increase in contractility 
in collagen contraction assays.  
Previous studies suggest that calcineurin may play an important role in the response 
to TGF-b in fibroblasts. First, TGF-b is known to lead to calcium influx and calcineurin 
activity in many cell types, including renal fibroblasts142. Davis et al. then demonstrated 
that the expression of the calcium channel TRPC6 independently stimulate myofibroblast 
differentiation in a manner very similar to TGF-b treatment; further, deletion of TRPC6 
rendered cardiac and dermal fibroblasts unable to differentiate into myofibroblasts in 
response to TGF-b, a phenotype that could be replicated. Notably, they identified that 
TRPC6 expression was induced by TGF-b through non-canonical signaling via p38 and 
SRF66. These findings demonstrating direct effects of TGF-b on calcium influx suggest 
that TGF-b signaling results in activation of calcineurin. Finally, there is also some 
evidence that CN and TGF-b signaling pathways can affect one another; in T cells, it has 
been shown that NFAT may act as a co-transcription factor with Smad2 and Smad3 to 
promote the expression of specific genes154,155.  
In summary, fibroblast activation in both cancer and fibrotic disease is often 
mediated by TGF-b, and calcineurin may at least partially regulate the fibroblast response 
to TGF-b stimulation. Therefore, we hypothesized that calcineurin deletion in fibroblasts 
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would abrogate their ability to respond functionally to TGF-b stimulation. Thus, we sought 
to examine the functional response of WT and Cn-/- lung fibroblasts to TGF-b treatment in 
vitro using many of the functional assays described in Chapter 2.  
 
Results 
Calcineurin deletion attenuates phenotypic changes in fibroblasts on collagen gels in 
response to TGF-b 
 To determine the effects of calcineurin deletion on TGF-b-induced activation, 
fibroblasts were grown on soft 1 mg/ml type I collagen gels and treated with and without 
2ng/ml TGF-b + 50 µg/ml ascorbic acid. Ascorbic acid was added to TGF-b treatment, as 
we have previously shown that the addition of ascorbate to TGF-b treatment can amplify 
FAP expression60. When WT fibroblasts are treated with TGF-b, they undergo a dramatic 
change in phenotype: the cells form large, globular clumps with cytoplasmic processes 
extending radially from them. Viability dye analysis reveals that these clumps of cells 
consist of a largely necrotic center surrounded by a surface of viable cells (data not shown). 
Notably, these TGF-b-induced phenotypic changes occurred to a much lesser extent in Cn-
/- fibroblasts (Figure 3.1). There was no difference in phenotype when WT fibroblasts were 
treated with AdCre, suggesting that this effect is not due to off-target effects of either 
adenovirus or Cre. Treating with TGF-b alone in the absence of ascorbic acid gave nearly 
identical results; thus, we performed the rest of our assays using TGF-b treatment alone in 
order to specifically isolate the role of CN in TGF-b-induced activation. 
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Calcineurin deletion alters TGF-b-stimulated changes in cytokine secretome 
 One crucial function of activated fibroblasts is their ability to secrete a variety of 
cytokines, chemokines, and growth factors that act in both autocrine and paracrine 
manners. It has previously been established that TGF-b treatment leads to alterations in the 
cytokine secretome in WT fibroblasts. Thus, we sought to determine which, if any, of these 
TGF-b-mediated changes in cytokine secretion might require CN signaling. Conditioned 
media collected from WT and Cn-/- fibroblasts cultured on soft type I collagen gels was 
analyzed for the expression of 40 cytokines using an antibody array (Figure 3.2A). We 
elected to focus on those specific cytokines whose secretion was differentially regulated 
(either increased or decreased) in WT fibroblasts upon TGF-b treatment: IL-6, IL-7, MIP-
1a, MIP-1b, and M-CSF (Figure 3.2B). Of these cytokines, MIP-1a, MIP-1b, and M-CSF 
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Figure 2.1: Phase-contrast imaging of fibroblasts cultured on soft type I collagen gels in the 
presence or absence of TGF-b. WT, WT treated with AdCre, or Cn-/- fibroblasts were plated on 
collagen gels in 1% serum containing media +/- 2 ng/ml TGF-b and 50 ug/ml ascorbic acid, and 
4x phase contrast images were taken at 72h. Scale bar = ~500 um.
Figure 3.1: Phase-contrast imaging of fibroblasts cultured on soft type I collagen gels in the 
presence or absence of TGF-b. WT, WT treated with AdCre, or Cn-/- fibroblasts were plated on 
collagen gels in 1% serum containing media +/- 2 ng/ml TGF-b and 50 ug/ml ascorbic acid, and 4x 
phase contrast images were taken at 72h. Scale bar = ~500 um. 
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were expressed at higher levels at baseline in Cn-/- fibroblasts. TGF-b treatment either 
increased or decreased levels of IL-6, MIP-1a, and MIP-1b in Cn-/- fibroblasts in a similar 
manner to WT. However, IL-7 and M-CSF levels were unaffected in Cn-/- fibroblasts upon 
TGF-b treatment, whereas they decreased in WT TGF-treated fibroblasts. Additionally, 
while TGF-b treatment did not alter TIMP-1 expression in WT fibroblasts, levels of TIMP-
1 decreased significantly in Cn-/- fibroblasts upon TGF-b stimulation. Taken together, this 
suggests that TGF-b-mediated regulation of IL-7 and M-CSF secretion are dependent on 
calcineurin signaling, and that CN may regulate TIMP-1 levels in the presence of TGF-b.  
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Figure 2.2: Cytokine antibody array analysis of WT and Cn-/- fibroblasts cultured on type I 
collagen gels with and without 2 ng/ml TGF-b. A. Heat map representation of all cytokines 
identified in the array. B. Bar graph of selected cytokines found to be differentially regulated in 
WT fibroblasts upon TGF-b treatment. N=1 per condition with 2 technical replicates per 
cytokine. 
Figure 3.2: Cytokine antibody array analysis of WT and Cn
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 fibroblasts 
cultured on type I collagen gels with and without 2 ng/ml TGF-b. A. 
Heat map representation of all cytokines identified in the array. B. Bar graph 
of selected cytokines found to be differentially regulated in WT fibroblasts 
upon TGF-b treatment. N=1 per condition with 2 technical replicates per 
cytokine.  
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TGF-b stimulation does not affect collagen contraction by calcineurin-null fibroblasts 
 We showed that calcineurin-null fibroblasts exhibit greater collagen remodeling 
and contraction when embedded in free-floating collagen gels; in these assays, we also 
treated free-floating collagen gels with TGF-b. As expected, when WT fibroblasts are 
treated with TGF-b, they increase their contractility and remodeling compared to 
unstimulated conditions; this difference persists for at least 72 hours following detachment 
of collagen gels (Figure 3.3, upper panel). However, TGF-b treatment does not affect 
contractility in Cn-/- fibroblasts, suggesting that calcineurin is required for TGF-b-mediated 
changes in collagen remodeling and contractility in fibroblasts (Figure 3.3, lower panel).  
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Figure 2.3: Collagen contraction assays of free-floating type I collagen gels with and 
without 2 ng/ml TGF-b. Images are of 3 technical replicates taken 24 h following collagen gel 
detachment. *p<0.05. N=1 experimental replicates.
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Calcineurin-null fibroblast migration is paradoxically inhibited by TGF-b in in vitro 
wound healing assays 
 We previously demonstrated that Cn-/- fibroblasts exhibit greater wound closure in 
in vitro scratch wound healing assays compared to WT. We have previously shown that 
TGF-b activation is crucial in inducing fibroblast migration in scratch assays156, so we also 
assessed wound closure of WT vs Cn-/- fibroblasts in the presence and absence of TGF-b. 
Phase contrast imaging revealed that TGF-b treatment caused WT fibroblasts to extend 
more cytoplasmic processes and orient themselves parallel to the scratch wound (Figure 
3.4A). However, TGF-b treatment did not significantly alter fibroblast orientation or 
morphology in Cn-/- fibroblasts, and fibroblast migration across the scratch wound 
appeared to be impaired in the presence of TGF. While TGF-b treatment did not 
significantly affect the rate of wound closure in WT fibroblasts as measured by decrease 
in wound area over time, live cell imaging showed significant differences in fibroblast 
motility, with greater fibroblast movement parallel to the wounded area and more 
individual fibroblasts migrating along the scratch wound. Conversely, there was little 
difference in morphology or motility of wounded Cn-/- fibroblast monolayers in the 
presence of TGF-b; in fact, wound closure rates were slower in Cn-/- fibroblasts when 
treated with TGF-b (Figure 3.4B). These findings demonstrate that unlike in WT 
fibroblasts, Cn-/- fibroblast motility may actually be hindered by the addition of TGF-b to 
scratch wound assays. 
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Calcineurin-null fibroblasts do not secrete or activate TGF-b in response to scratch 
wounding 
 Previous studies from our lab have shown that scratch wounding of WT cell 
monolayers leads to an increase in both total TGF-b secretion as well as latent TGF-b 
activation in a CD44-dependent manner156. Thus, we compared the amount of TGF-b in 
unwounded vs. wounded cell layers in WT and Cn-/- fibroblasts to determine whether the 
increased migration observed in Cn-/- fibroblasts is mediated by TGF-b secretion and/or 
activation. In order to better assess and amplify any differences in the activation of latent 
Figure 2.4: CN deletion paradoxically reduces fibroblast motility. A. Representative images 
from in vitro scratch wound healing assays with and without TGF-b. Image was taken 24 hours 
following initial wounding. Red dotted lines denote width of scratch at 0 hours post wounding. 
Contrast of phase images was adjusted for better visualization of fibroblasts. B. Quantification 
of live cell imaging of scratch assays. *p<0.05. Error bars = standard deviation. Data shown is 
from 1 of 2 experimental replicates, N=15 fields per condition.
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Figure 3.4: CN deletion paradoxically reduces fibroblast motility. A. Representative images 
from in vitro scratch wound healing assays with and without TGF-b. Image was taken 24 hours 
following initial wounding. Red dotted lines denote wid h of scratch at 0 hours post wounding. 
C ntrast of phase images was adjusted for better visualization of fibroblast . B. Quantification of 
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TGF-b, we added 30 ng/ml latent TGF-b1 at the time of wounding to all samples. Upon 
scratch wounding, the concentration of total TGF-b in the culture media increased in WT 
but not Cn-/- fibroblasts (Figure 3.5, left). However, while there was a trend toward 
increased levels of active TGF-b in wounded WT fibroblast layers, there were no such 
differences when Cn-/- fibroblast layers were wounded (Figure 3.5, right). Therefore, Cn-/- 
fibroblasts are unable to increase levels of either total or active TGF-b in response to 
scratch wounding.  
 
 
 
 
Smad phosphorylation in response to TGF-b is intact in calcineurin-null fibroblasts 
 Given the lack of functional response of Cn-/- fibroblasts to TGF-b stimulation, we 
wished to determine where specifically in the TGF-b signaling cascade signal transduction 
was impaired. Fibroblasts cultured on plastic were treated with 2 ng/ml TGF-b for 1 or 12h 
and analyzed via Western blot for Smad2 phosphorylation. In both WT and Cn-/- 
WT Cn-/-
Wounding - + - + - + - +
WT Cn-/-
Total Active
Figure 2.5: Quantitative sandwich ELISA of total and active TGF-b in unwounded and 
wounded WT and Cn-/- fibroblast monolayers. 30 ng/ml latent TGF-b1 was added to amplify 
latent TGF-b activation. For total [TGF-b], samples were pre-activated using HCl and diluted 
1:10 prior to analysis. Results were normalized to total protein content of cell layer lysates. 
N=5-7 per condition from a total of 3 separate experiments.
Figure 3.5: Quantitative sandwich ELISA of total and active TGF-b in unwounded and 
wounded WT and Cn-/- fibroblast monolayers. 30 ng/ml latent TGF-b1 was added to amplify 
latent TGF-b activation. For total [TGF-b], samples were pre-activated using HCl and diluted 1:10 
prior to analysis. Results were normalized to total protein content of cell layer lysates. N=5-7 per 
condition from a total of 3 separate experiments. 
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fibroblasts, Smad2 phosphorylation was induced following both 1 and 12 hours of TGF-b 
treatment, suggesting that calcineurin is not required for TGF-b-induced Smad2 
phosphorylation (Figure 3.6). 
 
 
 
Discussion 
 These data suggest that while calcineurin-null fibroblasts are activated at baseline, 
they are unable to respond functionally in response to TGF-b treatment. We demonstrate 
that CN is required for several phenotypic and functional changes induced by TGF-b in 
WT fibroblasts. The significance of the cell clumping phenomenon when WT fibroblasts 
are cultured on collagen gels and treated with TGF is still somewhat unclear; there is 
significant collagen remodeling as shown by both phase contrast and 2P-SHG imaging, 
suggesting that this alteration in morphology is directly related to fibrillar collagen re-
orientation. The clumping of cells could represent an increase in motility and/or 
proliferation. Given that proliferation assays have shown that treatment with TGF-b 
impairs fibroblast proliferation, it is more likely that the clumping observed is a result of 
Figure 2.6: Western blot with densitometric analysis of Smad2 phosphorylation in 
fibroblasts 1 and 12h following TGF-b treatment. Spaces between bands denote where 
unrelated bands on the same blot were excluded from the final image. N=1 per condition.
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Figure 3.6: Western blot with densitometric analysis of Smad2 phosphorylation in 
fibroblasts 1 and 12h following TGF-b treatment. Spaces between bands denote where 
unrelated bands on the same blot were excluded from the final image. N=1 per condition. 
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alterations in fibroblast motility and aggregation. Regardless of their functional 
significance, these changes do not occur in Cn-/- fibroblasts. 
 Similar to the angiogenesis array performed on WT and Cn-/- fibroblasts cultured 
on BME, secretome array analysis of cells cultured on soft type I collagen gels revealed 
global changes in the cytokine secretome of Cn-/- fibroblasts at baseline compared to WT. 
Our findings in WT fibroblasts are consistent with previous literature evidence regarding 
the effects of TGF-b on the fibroblast secretome; TGF-b has been shown to upregulate IL-
6 in human lung fibroblasts157, and there is evidence in macrophages that it can 
downregulate MIP-1a expression158. Further, the decrease in IL-7 and increase in M-CSF 
secretion induced in WT fibroblasts by TGF-b treatment may be dependent on CN 
signaling, as these changes were effectively abrogated in Cn-/- fibroblasts. Just as 
importantly, calcineurin does not appear to be required for TGF-b-mediated stimulation of 
IL-6, a pro-inflammatory and pro-fibrotic cytokine that has been implicated in the 
pathogenesis of pulmonary fibrosis159.  
Finally, we demonstrated that TGF-b treatment increased contractility in WT 
fibroblasts in collagen contraction assays, consistent with data from our and others’ prior 
studies. However, TGF-b did not affect contractility and/or remodeling of Cn-/- fibroblasts 
on type I collagen. Taken together, these three experiments show that CN deletion in 
fibroblasts renders them unable to respond to TGF-b stimulation when cultured on soft 
type I collagen. 
Further, we show that the increase in wound closure and alterations in cell 
morphology and orientation in Cn-/- fibroblasts compared to WT are not due to differences 
in TGF-b signaling. Since we had previously showed that scratch wounding led to 
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increased secretion and activation of TGF-b, and that Cn-/- fibroblast motility and 
morphology in scratch assays resembled WT TGF-treated fibroblasts, we hypothesized that 
Cn-/- fibroblasts might secrete or activate more TGF-b in scratch assays. However, levels 
of TGF in wounded Cn-/- fibroblast-conditioned media did not differ from WT, and 
wounding Cn-/- fibroblast monolayers did not lead to an increase in secretion or activation 
of TGF. Of note, in our assays, there was not a significant difference in TGF-b activation 
upon scratch wounding in WT fibroblasts, whereas previous studies have observed an 
increase in TGF-b activation in response to wounding. However, it is likely that ELISA-
based assay we utilized was less sensitive to small changes in active TGF-b compared to 
the reporter assay that was previously used.  
 Finally, we show that Cn-/- fibroblasts are capable of phosphorylating Smad2 in 
response to TGF-b treatment. This suggests that the block in TGF-b signaling in Cn-/- 
fibroblasts occurs either downstream or independently of Smad2 phosphorylation. These 
findings are consistent with previous literature, which has shown that calcineurin activation 
occurs via non-canonical TGF-b signaling. However, our results are complicated by the 
fact that these fibroblasts were cultured on tissue culture plastic, a substrate thousands of 
times stiffer than physiologic conditions. Due to this increase in substratum stiffness, the 
fibroblasts were already in an activated state and thus had a significant baseline amount of 
TGF-b secretion and Smad phosphorylation, possibly masking any further increases in 
response to TGF-b treatment. Future studies should investigate the mechanisms of Smad 
phosphorylation and other downstream aspects of TGF signaling on softer substrates such 
as collagen gels or polyacrylamide hydrogels as well as on fibroblast-derived matrices.  
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There are two main possibilities as to why Cn-/- fibroblasts may be unable to 
respond to TGF-b stimulus. First, calcineurin may be required for the signaling 
mechanisms downstream of TGF-b engagement with its receptor. The introduction to this 
chapter outlines specific literature evidence that TGF-b directly leads to calcium influx. 
Another possibility is that activation-related transcriptional programs are already active in 
Cn-/- fibroblasts due to dysregulation of fibroblast homeostasis. Thus, further treatment 
with an activating stimulus such as TGF-b would have no effect since these pathways have 
already been activated. At the same time, given the heterogeneity of activated fibroblasts, 
it is unlikely that a single transcriptional program is responsible for the entirety of the 
activated fibroblast phenotype. It is important to note, though, that these hypotheses are 
not mutually exclusive, and the lack of response to activating stimulus may be due to both 
decreased TGF-b-mediated calcium influx and increased transduction of activation-related 
signaling pathways in Cn-/- fibroblasts. 
 These experiments merely represent preliminary investigations into the role of CN 
signaling in the TGF-b response, and much remains to be investigated. First, it is crucial 
to determine specifically which parts of the TGF-b signaling pathway in fibroblasts are 
affected by calcineurin signaling. One way of achieving this is to further define which 
functional and transcriptional aspects of TGF-b-mediated activation require calcineurin 
signaling. Further understanding of alterations in NFAT targets upon TGF-b treatment 
would help determine how specifically calcineurin deletion leads to a functional inability 
to respond to TGF stimulation.  
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CHAPTER 4: THE EFFECTS OF STROMAL CALCINEURIN DELETION IN 
VARIOUS IN VIVO MODELS. 
 
Introduction 
 The in vivo data presented in Chapter 2 suggest that the phenotypic changes 
observed in lung fibroblasts in vitro are relevant to in vivo models of metastasis, as the pro-
tumorigenic changes observed in functional studies correlate with an increase in metastatic 
outgrowth in mouse models. However, it is also important to more broadly characterize the 
role of calcineurin signaling in fibroblasts in vivo, as fibroblasts play key roles in a large 
number of physiologic and pathologic processes. While few studies have been performed 
examining the role of CN in cancer-associated stroma in vivo, as discussed in Chapter 1, 
prior data suggest that stromal CN plays a role in a variety of other in vivo models, 
including fibrosis, wound healing, and cardiac remodeling. This chapter describes our 
efforts to define the effects of stromal CN deletion in several in vivo models, encompassing 
both physiologic and disease processes.    
 
Results 
Calcineurin is required for stiffness-dependent regulation of FAP but not aSMA expression 
 To assess how fibroblast activation is affected when CN is deleted from fibroblasts 
in vivo, we investigated fibroblast activation and activation marker expression in vitro on 
a substratum that mimicked in vivo conditions. We utilized a tunable polyacrylamide 
hydrogel system in order to replicate the stiffness of soft/less fibrotic (2 kPa) and stiff/more 
fibrotic (20-25 kPa) lung tissue in vitro160. When Cn-/- fibroblasts are grown on 2 kPa 
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fibronectin-coated hydrogels, they spread to a greater extent (Figure 4.1A). While the 
average cell size was the same in both groups, the distribution of cellular size of Cn-/- 
fibroblasts was shifted further to the right and had more weight in the right tail of the 
distribution (as measured by kurtosis) compared to WT fibroblasts, implying that Cn-/- 
fibroblasts had a higher proportion of large, spread cells when cultured on soft hydrogels  
(Figure 4.1B). Unlike on soft substrates, there were no noticeable differences in 
morphology between WT and Cn-/- fibroblasts when cultured on 25 kPa hydrogels. We 
have previously observed that 2 kPa fibronectin-coated hydrogels select for a FAPhi 
population in WT fibroblasts, whereas stiffer substrates shift the fibroblast phenotype to 
one that is aSMAhi and more myofibroblastic60. FAP and aSMA expression by WT and 
Cn-/- fibroblasts on hydrogels was assessed by flow cytometry and revealed that Cn-/- 
fibroblasts are unable to upregulate FAP on soft substrates, while aSMA expression is 
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Figure 3.1: Imaging and flow cytometric analysis of WT and Cn-/- fibroblasts cultured on 
fibronectin-coated hydrogels. A. Phalloidin staining of B. Cell area analysis of fibroblasts on 2 
kPa hydrogels was performed using ImageJ. Kurtosis of size distributions was measured using 
Prism GraphPad. C. Summary of flow cytometric analysis of FAP and αSMA experiments of 
WT and Cn-/- fibroblasts cultured in full serum media for 48 hours. 
B
Figure 4.1: Imaging and flow cytometric analysis of WT and Cn-/- fibroblasts cultured on 
fibronectin-coated hydrogels. A. Phalloidin staining of B. Cell area analysis of fibroblasts on 2 kPa 
hydrogels was performed using ImageJ. Kurtosis of size distributions was measured using Prism 
GraphPad. C. Summary of flow cytometric analysis of FAP and αSMA experiments of WT and Cn-/- 
fibroblasts cultured in full serum media for 48 hours. Error bar = standard deviation, *p<0.05. 
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comparable to that of WT fibroblasts. These data suggest that CN deletion alters both 
cytoskeletal morphology and FAP expression of fibroblasts on soft, but not stiff, substrates.  
 
Loss of CN in fibroblasts does not affect tumor cell colonization of the lung 
While the injection-resection model of metastasis we utilized is a physiologically 
relevant model of spontaneous metastasis, it cannot specifically identify which aspect of 
metastasis is altered by stromal calcineurin deletion, such as extravasation, intravasation, 
or colonization. We investigated the role of stromal calcineurin deletion in tumor cell 
migration, lung colonization, and micrometastatic formation using intravenous tumor cell 
injection. We injected WT and stromal CN-null mice (Col1a1-Cre) intravenously into the 
lateral tail vein with SKPY42.1 cells, a YFP-expressing clonal cell line isolated from a 
model of undifferentiated pleomorphic sarcoma featuring oncogenic Kras and p53 
deletion161. We observed no significant difference in lung colonization between the WT 
and Col1a1-Cre mice as measured by H&E staining at multiple time points (Figure 4.2A). 
Flow cytometry of murine lungs for YFP+ tumor cells revealed an increase in cell number 
at 4 days in Col1a1-Cre mice following tumor cell injection; however, this difference was 
highly variable and not statistically significant (Figure 4.2B). Quantification of YFP+ 
tumor cells in the lung at later timepoints by flow cytometry also did not reveal any 
differences between WT and stromal CN-null mice. Taken together, these data show that 
colonization of the lung by sarcoma cells is not affected by stromal CN deletion.  
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Stromal calcineurin deletion alters collagen content in the lung at baseline 
 Prior studies suggest that CN signaling may modulate fibrosis, and chronic 
calcineurin inhibition is associated with fibrotic disease. Therefore, we examined the role 
of stromal CN deletion in a bleomycin-induced model of lung fibrosis using Masson’s 
trichrome staining of lung sections and quantification of total collagen (blue) signal. 
Col1a1-Cre mice in the absence of bleomycin demonstrated a trend toward higher amounts 
of collagen in the lung compared to WT; however, there was no difference in collagen 
content between WT and Col1a1-Cre mice treated with bleomycin (Figure 4.3). chis 
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Figure 3.2: Summary of intravenous injection experiments of YFP+ sarcoma cells in WT
and stromal CN-null mice. A. Table summary of all tail vein injection experimental conditions
and results. Lungs were analyzed for tumor burden using H&E staining of lung sections. B.
Flow cytometric analysis of total YFP+ cell content in murine lungs at early (left) and late (right)
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suggests that stromal CN deletion may lead to baseline differences in collagen content in 
the lung but does not affect the fibrotic response to bleomycin in this model.  
Stromal calcineurin deletion does not alter kinetics of dermal wound closure 
 Previous literature has identified a potential role for calcineurin signaling in dermal 
wound healing66; therefore, we elected to study the kinetics of wound healing in mice with 
stromal CN deletion using bilateral punch biopsies on the dorsal skin. We observed no 
difference in wound closure kinetics between CnBfl/fl and Col1a1-Cre;CnBfl/fl mice (Figure 
4.4), suggesting that stromal CN is not required for timely wound closure. 
p=0.056
ns
Figure 3.3: Col1a1-Cre;CnBfl/fl mice accumulate more collagen in the lung at baseline.
Masson’s trichrome images were analyzed using ImageJ for total collagen (blue) area
normalized to total lung area. One point = one mouse.
Col1a1-Cre
Bleomycin
+-
+- +-
Figure 4.3: Col1a1-Cre;CnBfl/fl mice accumulate more collagen in the lung at baseline. Masson’s 
trichrome images were analyzed using ImageJ for total collagen (blue) area normalized to total lung 
area. One point = one mouse. Data synthesized from N=2 experiments. Error bar = standard deviation. 
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Discussion 
 We demonstrated that stromal CN deletion using the Col1a1-Cre-ER(T);CnBfl/fl 
mouse did not affect outcomes in models of lung tumor cell colonization, lung fibrosis, and 
dermal wound healing. However, study of fibroblast morphology and activation marker 
expression using a physiologically relevant 3D culture demonstrated that stiffness-
dependent modulation of FAP, but not aSMA, on fibronectin-coated substrata may require 
calcineurin signaling.  
 Our data suggest that deletion of calcineurin in lung fibroblasts alters cell 
morphology when cultured on fibronectin-coated hydrogels tuned to physiologically 
relevant stiffness. Consistent with our previous studies, we showed that on soft (2 kPa) 
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Figure 3.4: Stromal CN deletion does not alter the kinetics of dermal wound closure. 6mm
dermal punch biopsies were performed bilaterally on the dorsum of mice. Wound images were
taken every other day using a digital camera, and wound size was measured using ImageJ.
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fibronectin-coated hydrogels, WT fibroblasts expressed FAP at higher levels compared to 
when they are cultured on stiff (20-25 kPa) fibronectin-coated hydrogels. In comparison, 
Cn-/- fibroblasts did not upregulate their expression of FAP when they are cultured on soft 
hydrogels. Calcineurin deletion did not affect stiffness-dependent regulation of aSMA 
expression. Similarly, Cn-/- fibroblasts exhibited increased cell spreading compared to WT 
on soft, but not stiff, hydrogels, suggesting that CN deletion may specifically affect the 
FAP+ population of fibroblasts. These results are not consistent with the literature findings 
mentioned in Chapter 1, which suggest that calcineurin is required for the aSMA+ 
myofibroblast phenotype. However, it is likely that the CN-mediated regulation of 
activation marker expression is substratum-dependent; for example, preliminary data 
suggests that FAP is upregulated in Cn-/- fibroblasts compared to WT when they are 
cultured on type I collagen gels (data not shown). At the same time, analysis of the 
promoter regions of FAP and aSMA show that FAP contains multiple consensus binding 
sequences for NFAT, whereas aSMA does not (see Conclusions and Future Directions). 
It may be that NFAT directly regulates FAP expression but not aSMA, but that CN/NFAT 
modulates the myofibroblast phenotype and aSMA expression indirectly by affecting 
transduction through other signaling pathways.  
 One possibility that might explain these negative results in vivo is that calcineurin 
deletion in lung fibroblasts at the protein level was only partial (~60% deletion) despite 
observing high levels of Col1a1-Cre expression via qPCR. Residual CN-expressing 
fibroblasts may have been sufficient to mask subtle differences in disease progression in 
these models. There are several possibilities as to why CN was not completely deleted from 
fibroblasts in vivo. First, Col1a1-Cre expression may vary significantly in various 
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subpopulations of lung fibroblasts. Expression of the 2.3kb fragment of the Col1a1 
promoter had not previously been assessed in adult lung fibroblasts, and we demonstrated 
its expression via qPCR. However, while the complete Col1a1 promoter is expressed in all 
fibroblasts, the 2.3kb fragment may only be expressed in certain fibroblast subpopulations, 
leading to incomplete deletion of CN in all lung fibroblasts. Second, despite continually 
administering tamoxifen, stromal precursors that do not yet express Cre via the Col1a1 
promoter may still be actively recruited from the bone marrow and escape deletion in this 
manner. A third possibility is that the process of isolation via selection for adherent 
fibroblasts artificially selects for those fibroblasts that did not undergo CN deletion due to 
differences in adhesion and/or proliferation of Cn-/- fibroblasts.   
 However, it may be that stromal CN deletion is sufficient to cause phenotypic 
differences in these lung fibroblasts, but that we did not observe differences in these disease 
models for other reasons. First, while intravenous tumor cell injections are a commonly 
utilized experimental model of tumor cell colonization in the lung, this approach is not the 
most physiologically relevant or accurate model of lung metastasis. Primary tumors are 
known to secrete circulating factors, including cytokines and exosomes, that prime the lung 
for metastasis. In the absence of primary tumor conditioning, there may be no significant 
differences in lung colonization at baseline. Additionally, our intravenous tumor 
colonization assays utilized sarcoma tumor cells; unlike the Lewis lung carcinoma and 
PDAC cells used in our injection-resection assays, these tumor cells are of mesenchymal 
origin. Because of this, their interactions with the microenvironment are likely different 
compared to epithelial tumor cell lines. Indeed, the majority of studies examining the role 
of fibroblasts in cancer have been performed in epithelial tumor cell lines, and the role of 
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activated fibroblasts in mesenchymal tumors is less well defined. Therefore, it may be that 
SKPY42.1 colonization and outgrowth are unaffected by stromal CN deletion, whereas 
LLC or PDAC would demonstrate significant differences in one or both of these metrics. 
Future studies will specifically examine the effects of stromal CN deletion on PDAC 
colonization and outgrowth.  
 Next, the bleomycin lung fibrosis assays are complicated by the fact that the lung 
fibrosis we observed was not statistically significant in WT mice. That having been said, 
the increase in collagen content in the lungs of untreated Col1a1-Cre mice is consistent 
with our in vitro findings that Cn-/- fibroblasts are more activated in the absence of 
activating stimuli compared to WT. By increasing the bleomycin dosage, number of doses, 
or by administering the bleomycin intratracheally instead of intraperitoneally, the amount 
of fibrosis induced would be significantly greater, possibly amplifying any differences in 
lung fibrosis between WT and stromal CN-null mice. Even if stromal CN deletion is shown 
to increase lung fibrosis, this difference may instead be due to the increase in collagen 
content seen at baseline; therefore, a more relevant metric might be to compare the increase 
in collagen content between untreated and bleomycin-treated conditions. This would 
specifically assess whether stromal CN leads to more or less robust induction of fibrosis 
upon exposure to bleomycin. 
 Finally, in the case of dermal wound healing, wound closure kinetics may not be 
the most relevant measurement by which to analyze the mechanism of wound healing in 
stromal CN knockout mice. Our lab has previously shown that CD44 deletion in mice does 
not affect the time it takes for a dermal wound to close; however, the kinetics of fibroblast 
activation and ECM reorganization in the healing wound are significantly altered162. Thus, 
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future studies should focus on the fibroblast activation and ECM dynamics in the 
developing dermal wound in order to determine whether or not stromal CN deletion affects 
these particular readouts. 
 Taken together, these results highlight the importance of selecting physiologically 
and experimentally relevant biological assays. While the negative results seen may 
represent the fact that stromal CN deletion indeed has no effect on lung colonization, 
bleomycin-induced fibrosis, or dermal wound healing, it is important to further optimize 
experimental conditions to ensure maximal likelihood that any true differences are 
detected. Additionally, the functional assays in vitro identified a specific role for CN in 
maintenance of the quiescent, homeostatic state. It may be of greater interest to further 
assess these mice in non-disease-stimulated settings and profile their tissues at baseline, as 
stromal CN may lead to greater amounts of activation and fibrosis in the absence of disease 
compared to WT. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Taken together, my work demonstrates that calcineurin plays an important role in 
fibroblast homeostasis and activation, the response to TGF-b stimulation, and tumor 
growth in vitro and in vivo. I showed that calcineurin deletion leads to a baseline phenotype 
consistent with an activated, pro-tumorigenic, CAF-like state in lung fibroblasts, and that 
this phenotype promotes metastatic outgrowth in vivo. Then, I outlined preliminary work 
that shows that calcineurin is required for fibroblasts to functionally respond to TGF-b 
stimulation. Finally, I further examined the role of stromal CN deletion in a number of in 
vivo assays. This work has identified an important regulator of fibroblast homeostasis that 
may also mediate their ability to respond to activating stimuli such as TGF-b. Future 
studies should seek to further define the disruption of homeostasis by CN deletion, delve 
into the specific transcriptional mechanisms behind the functional phenotype of CN-null 
fibroblasts, and investigate other aspects of the effects of stromal CN deletion in vivo. 
 
 
 
Figure 5.1: Schematic describing the role of calcineurin in maintaining fibroblast homeostasis. 
Illustration of fibroblasts adapted from Kanasaki et al, Front. Endo 2013. 
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Calcineurin regulates functional fibroblast homeostasis 
Collectively, my data demonstrate that calcineurin deletion from fibroblasts leads 
to a phenotype that is overall consistent with greater activation “at baseline.” First, it is 
important to recognize that the “baseline” at which fibroblasts are studied is still far from 
the quiescent conditions that would be observed in vivo. Tissue culture plastic has an elastic 
modulus in the gigapascal range, several orders of magnitude stiffer than the majority of 
tissues in the body; therefore, when fibroblasts are cultured on traditional tissue culture 
dishes, they are activated by this significant increase in mechanical stiffness. While my 
experiments were often performed on soft (<1kPa) type I collagen gels or tuned 
polyacrylamide hydrogels, all primary fibroblasts were still isolated by selecting for 
adherent cells on tissue culture plastic, and they were cultured on either uncoated or gelatin-
coated tissue culture dishes prior to use in experiments. We and others have shown 
significant plasticity of the fibroblast phenotype, with fibroblasts able to downregulate 
aSMA expression when they are moved from a stiff to a soft substratum60,85. While 
passaging cells onto a softer substrate may partially “deactivate” these primary fibroblasts, 
there is evidence that activation of fibroblasts can induce long-term epigenetic 
modifications57, and the effects of even transient culture on substrata of supraphysiologic 
mechanical stiffness cannot be discounted.  
My data identify a role for CN signaling in several functional readouts of fibroblast 
activation, especially those related to the deposition and remodeling of extracellular matrix. 
The functional changes upon deletion of CN in fibroblasts lead to an activated, pro-
tumorigenic, more CAF-like phenotype. Deletion of CN leads to the formation of 
fibroblast-derived matrices that have a greater amount of, more linearized, and parallel-
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oriented collagen fibers; the architecture of Cn-/- FDMs is consistent with a TACS-2 to 
TACS-3 collagen signal, whereas WT FDMs more closely resemble TACS-1. The 
differences between WT and Cn-/- FDMs parallel the changes in collagen architecture 
during tumor progression. When PDAC tumor cells are cultured on Cn-/- FDMs, they 
become more migratory and adopt a more elongated morphology, two behaviors that are 
often consistent with greater tumor cell invasion. Whether the changes in morphology and 
motility observed in PDAC cells are associated with greater epithelial-mesenchymal 
transition (EMT) on Cn-/- FDMs compared to WT FDMs is an interesting question that 
should be addressed in the future.  
Another important, still unanswered question is whether the phenotype of CN-null 
fibroblasts we have observed relies on NFAT signaling, and if so, which activation-
associated genes are regulated by NFAT. While there is not yet evidence of calcineurin-
mediated regulation of the expression of many activation-associated genes, we have shown 
that many of these genes contain at least one NFAT binding site, suggesting that NFAT is 
at least capable of either activating or repressing their transcription. Using ConTra V3, an 
online resource that allows for the identification and visualization of primer binding sites 
in genes from a variety of organisms163, we identified a number of activation-associated 
murine genes that contained at least one NFAT binding consensus sequence, including 
fibroblast activation protein (FAP) and several collagen genes, suggesting that NFAT 
signaling may specifically be able to modulate the phenotypes we observed (data not 
shown). It is important to note that because NFAT requires a transcriptional co-factor for 
optimal DNA binding, a gene does not necessarily need to contain an NFAT consensus 
sequence in order for it to be regulated by NFAT. Because NFAT has weak DNA-binding 
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capabilities that often require co-activation by another transcription factor, the presence of 
an NFAT binding site in a gene’s promoter is not sufficient evidence that it is regulated by 
NFAT in vivo. 
More recently, the general philosophy surrounding activated fibroblasts has shifted 
to define a cell state of “activation” rather than the cell type of “activated fibroblast57.” 
Similarly, quiescence is now thought of as a state requiring active maintenance as opposed 
to a default cellular state. My data suggest that calcineurin is required to maintain the 
quiescent state, restrain the activated state, or, possibly, both. One complication with many 
of the studies that claim to “deprogram” activated fibroblasts into a quiescent state is that 
they often introduce genetic alterations or drug treatment prior to exposure to the activating 
stimulus, thus instead showing that these perturbations block activation. Thus, it will be 
critical to assess the role of calcineurin both in maintaining homeostasis in quiescent 
fibroblasts as well as potentially deprogramming or “deactivating” activated fibroblasts. 
While my work is the first to identify a role for CN specifically in fibroblast 
homeostasis, CN deletion or inhibition has been shown to disrupt homeostasis in many 
other cell types and disease models. One of the main methods through which calcineurin 
inhibitors prevent transplant rejection is by promoting the recruitment and activity of 
myeloid-derived suppressor cells (MDSCs); further, evidence suggests that CN/NFAT may 
control homeostasis of many innate immune cell populations137,138. Additionally, inhibition 
of calcineurin has been shown to induce tumor-promoting effects in keratinocytes, which 
may partially account for the increase in cutaneous squamous cell carcinomas seen in 
patients treated long-term with calcineurin inhibitors139. In neurons, calcineurin modulates 
retinoic acid synthesis, and prolonged calcineurin inhibition leads to an increase in 
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excitatory neuron activity and a loss of homeostatic synaptic plasticity140. Therefore, there 
is a precedent for CN playing a role in homeostasis.   
Further, despite their activation at baseline, my data show that Cn-/- fibroblasts are 
unable to respond to specific activating stimuli. Unlike WT fibroblasts, they do not 
significantly remodel their secreted matrix when treated with tumor cell-conditioned media 
compared to control media. Tumor-conditioned media consists of a large number of 
different growth facts, cytokines, chemokines, and exosomes secreted by tumor cells, and 
it is unclear which of these factors are responsible for the remodeling of FDMs observed 
in WT fibroblasts, or which of these factors requires CN for their secretion. Given that my 
data identified an impaired functional response to TGF-b in Cn-/- fibroblasts, and because 
many tumors secrete TGF-b, it may be that the inability of Cn-/- fibroblasts to respond to 
tumor-conditioned media is at least partially mediated by TGF-b. In order to test this 
hypothesis, fibroblast-derived matrices could be generated in the presence and absence of 
TGF-b to determine whether TGF-b treatment alone is sufficient to induce these changes 
in FDM architecture in WT fibroblasts. TGF-b neutralizing antibodies could also be added 
to tumor-conditioned media to determine whether TGF-b signaling is required for tumor 
cell-induced changes in WT FDMs.  
 
Future directions to further characterize the role of CN in fibroblast homeostasis 
 In order to complement the current genetic deletion studies, pharmacologic 
inhibition of CN should be performed to determine whether inhibition of phosphatase 
activity of CN is sufficient to recapitulate the phenotype observed in CN-null fibroblasts. 
Additionally, specifically inhibiting NFAT would help to determine whether the activation 
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of fibroblasts upon deletion of CN is dependent on NFAT-mediated transcription. Initial 
studies comparing CsA and FK506/tacrolimus treatment in WT fibroblast-derived matrices 
demonstrated that CsA treatment of WT fibroblasts leads to thinner matrices than vehicle 
treatment; conversely, FK506 treatment leads to an increase in matrix content and 
alignment very similar to that seen in Cn-/- fibroblasts (data not shown). Consistent with 
previous literature showing that CsA has anti-fibrotic effects independent of calcineurin 
inhibition117, this suggests that the differences in Cn-/- FDMs observed are in fact due to a 
reduction in calcineurin activity as opposed to Cre or adenoviral treatment. However, 
preliminary data suggests that FK506 increases fibroblast proliferation, which we did not 
observe in CN-null fibroblasts. As with any drug, FK506 likely has off-target effects 
independent of calcineurin inhibition that may also be affecting these assays. Future 
experiments would assess the effects of FK506 or the NFAT inhibitor VIVIT on functional 
assays in order to determine whether the CN-null phenotype requires calcineurin 
phosphatase activity and/or NFAT-mediated transcription. 
One of the most important next steps in the study of calcineurin and fibroblast 
homeostasis is to determine the exact transcriptional changes that mediate the functional 
differences we have observed upon deletion of CN. First, the NFAT isoforms primarily 
responsible for fibroblast activation must be identified. Initial immunofluorescence for 
NFAT isoforms has been performed but requires optimization. In this experiment, 
fibroblasts treated with various activating stimuli would be probed for nuclear localization 
of all four NFAT isoforms in order to determine which translocate to the nucleus upon 
activation. Once the predominant NFAT isoforms have been identified, loss- and gain-of-
function experiments using deletion or overexpression of specific isoforms could be 
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performed to determine whether this phenocopies the results seen in Cn-/- fibroblasts. 
Additionally, ChIP for activation-associated genes would determine whether NFAT 
occupancy of these genes is altered upon fibroblast activation; ChIP-seq analysis would 
identify global changes in NFAT occupancy in the presence of an activating stimulus such 
as TGF-b or an increase in substratum stiffness.  
While my work has identified how CN deletion affects several functions of 
activated fibroblasts, it is still unclear how CN regulates their transdifferentiation into 
specific subtypes of activated fibroblasts. One aspect of fibroblast activation that is 
incompletely studied in my work is the heterogeneous nature of activated fibroblasts, and 
indeed, fibroblasts in general. Beyond FAP and aSMA, a large number of other activated 
fibroblast markers define a large number of subsets of activated fibroblasts. While these 
markers often overlap, completely profiling the activation markers expressed by Cn-/- 
fibroblasts at baseline and in the presence of activating stimuli such as TGF-b or 
mechanical stiffness would help to define how exactly calcineurin modulates fibroblast 
activation, and in which populations. Better knowledge of how CN informs fibroblast 
heterogeneity will identify which specific subsets of activated fibroblasts are targeted by 
calcineurin inhibitor therapy, thus better defining the specific effects on the stroma as well 
as the tumor microenvironment in general.  
Future experiments should also characterize the role of CN in fibroblast-mediated 
remodeling of the ECM and subsequent cytoskeletal reorganization of fibroblasts cultured 
on WT vs Cn-/- FDMs. The effects of CN deletion on expression and activity of MMPs as 
well as lysyl oxidase (LOX) and other collagen cross-linking enzymes should be 
investigated, as these remodeling enzymes are known to contribute to the linearization of 
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collagen fibers during matrix remodeling. While my studies have focused on the role of 
CN in fibroblast-mediated collagen deposition and remodeling, the effects of CN deletion 
on other ECM proteins should be studied as well. As mentioned in Chapter 1, the ECM 
consists of significant amounts of fibronectin and hyaluronic acid, among other proteins, 
whose secretion and structure can be altered by activated fibroblasts. Expression analysis 
of a wide variety of ECM proteins and matrix remodeling enzymes at both the mRNA and 
protein levels would determine whether the increase in fibrillar collagen signal induced by 
Cn-/- fibroblasts in type I collagen gels and FDMs is due to increased ECM expression, 
increased matrix remodeling, or both. 
 The immediate next steps to identify the specific role that calcineurin plays in TGF-
b-mediated activation are, as previously discussed in Chapter 3, to examine the canonical 
and noncanonical TGF-b signaling pathways downstream of receptor binding and Smad 
phosphorylation to better examine where the specific block in signaling is located. Further 
studies with a large variety of activating stimuli should be performed to specifically 
identify the role of CN in each of these settings. This will determine whether CN signaling 
is required for the response to specific stimuli or more generally restrains fibroblast 
activation in response to all activating stimuli.  
 While we have shown that deletion of calcineurin leads to a phenotype consistent 
with fibroblast activation, it is also important to determine whether the converse is true, i.e. 
if increased activation of the calcineurin/NFAT pathway induces a quiescent fibroblast 
phenotype. This will identify whether calcineurin maintains homeostasis, suppresses 
activation, or both. This can be accomplished either by expressing a constitutively active 
mutant of CN or NFAT, or by deleting an endogenous calcineurin inhibitor such as Dscr1. 
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However, our work using the Dscr1-null mouse demonstrates that the response to 
calcineurin signaling often follows a bell-shaped curve; either too little or too much 
calcineurin signaling can have similar effects105. It may be that excessive activation of 
calcineurin signaling also has an activating effect in lung fibroblasts, as was observed by 
Davis et al164.  
  
Stromal CN deletion restrains metastatic outgrowth 
The studies examining stromal CN deletion in mice I have performed show that 
stromal CN in the lung serves to restrain lung metastasis growth; deletion of CN from lung 
fibroblasts encourages outgrowth of lung metastases, leading to larger tumor sizes. This 
could be through a variety of mechanisms. First, Finally, the alterations in secretion and 
remodeling of extracellular matrix could create a pro-tumorigenic collagen signature in 
both the lung and the metastases; as the FDMs represented a shift from TACS 1-2 to TACS 
2-3 upon calcineurin deletion, the effects on matrix in vivo could similarly remove 
collagen-induced restraints on tumor growth. However, picrosirius red staining reveals that 
fibrillar collagen content in PDAC lung metastases is minimal, and there is not a noticeable 
capsule around these tumors. Therefore, the effects of stromal CN deletion could also 
include other components of the ECM that also affect tumor outgrowth, such as fibronectin.  
In addition, my work broadens the understanding of the expression pattern 2.3kb 
fragment of the Col1a1 promoter. Previous work had suggested that this fragment of the 
promoter was specific only to osteoblasts and osteoclasts and expressed at lower levels in 
dermal fibroblasts. However, the previous studies only examined expression in lung 
fibroblasts of embryonic mice whose mothers had been given tamoxifen, and expression 
 
 
79 
in adult lung fibroblasts had not yet been assessed. I have shown that the 2.3kb-Col1a1-
Cre-ER(T) is expressed in lung fibroblasts by qPCR and by demonstrating CN deletion in 
isolated lung fibroblasts. This underlines the importance of examining tissue-specific 
promoter expression in adult as well as embryonic mice. 
As was discussed previously, one of the difficulties inherent in studying the effects 
of tissue-specific gene deletion in vivo is that the correct disease model, time points, and 
variables must be chosen in order for the results to be physiologically relevant, or in our 
case, even detected in the first place. It is important to consider that in vivo models featuring 
activated fibroblasts may not in fact be the best method of studying stromal CN deletion. 
Given that our major in vitro phenotypes exist in the absence of activating stimuli, it may 
be that stromal CN deletion has long-term effects on normal tissues due to the constant 
activation of fibroblasts. 
 
Future directions to characterize the effects of stromal CN deletion in vivo 
 There remains a significant amount of phenotypic profiling of the stromal CN-null 
mouse that needs to be performed. First, given that calcineurin deletion in vitro led to 
significant phenotypic differences in baseline states as opposed to activated states, the 
lungs and skin of these mice should be analyzed for baseline collagen content and 
architecture, as well as fibroblast activation marker expression. In addition, aging-related 
organ fibrosis (e.g. renal, dermal, pulmonary, and cardiac fibrosis) should be compared 
between WT and stromal CN-null mice; while aging is a process that involves 
inflammation and fibroblast activation, increased amounts of baseline stromal activation 
may shift the kinetics and/or increase the severity of aging-related fibrosis. By lowering 
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the “activation threshold” of fibroblasts, aging-related changes such as fibrosis and 
senescence may be more dramatic in the setting of stromal CN deletion. 
 As previously discussed, future experiments should also continue and expand on 
the investigation of the role of stromal CN deletion in various disease models. Bleomycin 
lung fibrosis and dermal wound healing assays could be modified in a way that maximizes 
the differences between WT and stromal CN-null mice. There are also many aspects of 
both primary tumors and lung metastases that could be investigated, such as the effects of 
CN deletion on immune surveillance, tumor angiogenesis, and collagen 
architecture/remodeling over the course of tumor growth and progression. The tumors that 
were resected in our models of metastasis were sufficiently large to have already surpassed 
the angiogenic and stromagenic switches, and analyzing large tumors may not detect 
differences in a model in which activation and homeostasis are affected in baseline 
conditions. This may explain why preliminary studies examining the vasculature in these 
resected tumors did not demonstrate large differences in vessel density. Our data suggest 
that stromal deletion of CN may alter very early stages of micrometastatic outgrowth in a 
lung colonization model of tumor growth. Thus, analysis of primary tumors and metastases 
should be performed at multiple time points starting at very early stages to determine the 
effects of stromal CN deletion on the kinetics of stromal activation in tumorigenesis and 
metastasis. It may be that lowering the activation threshold by deleting calcineurin leads to 
earlier triggering of the angiogenic and/or stromagenic switch.   
 Finally, to complement the current model, deletion of  CN  from the stroma could 
be performed using a variety of other methods. First, I have obtained a mouse expressing 
Cre-ER(T) driven by the Col1a2 promoter, a promoter that is known for being more 
 
 
81 
broadly expressed across all fibroblasts and connective tissue in the body, and am in the 
process of crossing this mouse to CnBfl/fl mice in order to potentially achieve higher 
proportions of CN deletion in lung fibroblasts, as well as to compare the effects of CN 
deletion in fibroblasts expressing the Col1a1 vs Col1a2 promoter. Additionally, use of 
other fibroblast or activated fibroblast promoters in the deletion of CN would complement 
the in vitro phenotypic profiling experiments mentioned above; by deleting calcineurin 
specifically from aSMA, FAP, or PDGFR-expressing fibroblasts, for example, we would 
be able to better understand the ways in which CN expression is required for the 
homeostasis or activation of those specific fibroblast sub-populations.  
 
Clinical implications 
This work identifies another possible mechanism through which chronic 
calcineurin inhibition may lead to increased malignancy in transplant patients. Previously, 
the pathophysiology of calcineurin inhibitor-induced malignancy had been mainly 
suggested to be via its immune suppressive properties101. However, our data suggest that 
another mechanism through which these drugs may lead to an increase in tumor formation 
is through their effects on the stroma. Some of the pro-tumorigenic effects of calcineurin 
inhibition on the stroma may in fact have effects on the immune system through decreased 
immune surveillance of tumors or increase in overall inflammation. However, we showed 
that calcineurin deletion leads to pro-tumorigenic changes in collagen deposition, 
remodeling, and contractility, thus it is very likely that chronic calcineurin inhibitor 
treatment also leads to the formation of pro-tumorigenic ECM in tissues, thus facilitating 
the formation of malignancies. By understanding the mechanism through which chronic 
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calcineurin inhibition might create a tumor-permissive stroma, we can potentially develop 
drugs that prevent this baseline stromal activation and at least partially mitigate the increase 
in malignancy and fibrotic disease observed in transplant patients.  
It is important to note that our work furthers the biological understanding of CN-
mediated fibroblast homeostasis, but there is still a significant amount of work that remains 
in order for this to translate to specific therapies in the future. Given that calcineurin plays 
such important and vastly differing roles in different tissues, any modality that broadly 
targets calcineurin/NFAT will likely have significant on- and off-target effects that will 
complicate or likely render these therapies ineffective. Because of this, further work needs 
to be performed in order to determine more specific downstream targets of CN/NFAT 
signaling as previously described. Given its role as a homeostatic regulator, there are two 
potential methods of targeting CN/NFAT signaling in a way that abrogates fibroblast 
activation. First, certain pro-activation genes can be negatively targeted to block stromal 
activation, a modality that is currently being studied to varying degrees of success as 
discussed in Chapter 1. Second, and more novel, specific homeostatic regulators could be 
positively targeted to increase their function and maintain fibroblast homeostasis in the 
face of activating stimuli such as cancer or inflammation. Before clinical therapies can be 
developed, further work needs to be done to identify the specific molecular mechanisms 
through which calcineurin maintains the quiescent fibroblast phenotype. 
There are several potential clinical-translational applications of this data. Increased 
understanding of the ways in which CN regulates specific fibroblast activation-associated 
genes could be used to better target the activation of stromal cells in both the primary tumor 
and distant metastatic sites. However, just as targeting angiogenesis alone resulted in 
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limited efficacy, so too will stroma-targeting therapies likely need to be used in 
adjunctively with other methods of treatment. Ideally, inducing homeostasis or blocking 
activation through CN-mediated processes would increase the efficacy of other cancer 
therapies, such as traditional chemotherapy or immunotherapy. That having been said, as 
early cancer screening and detection continues to improve, we may be able to use these 
modalities to target the stroma at the distant site in a way that prevents the colonization 
and/or outgrowth of metastases, so that patients with early-stage cancer may receive these 
treatments in order to ensure that their disease does not progress.  
In conclusion, my work has identified CN as a novel regulator of fibroblast 
homeostasis. While further studies will be required in order to translate these findings into 
clinical therapies, these data raise interesting questions regarding the maintenance of the 
quiescent and activated states in fibroblasts, and they provide potential alternate 
mechanisms for the increase in tumorigenesis observed in transplant patients receiving 
long-term calcineurin inhibition therapy. 
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MATERIALS AND METHODS 
 
Primary lung fibroblast isolation and culture 
Fibroblasts were cultured in DMEM-F12 + L-glutamine (Gibco) with 10% heat-
inactivated FBS, L-glutamine, and penicillin-streptomycin. To isolate primary lung 
fibroblasts, lungs from male and female 3-5-week-old mice were dissociated in Hank’s 
buffered saline solution (HBSS) containing 5 mg/ml type II collagenase and 0.5 mg/ml 
deoxyribonuclease I (Worthington, #LS004176 and #LS002139) in the Miltenyi 
GentleMACS Octo. Dissociated lungs were passed through 100µm and 40µm filters to 
obtain a single cell suspension before resuspending in culture media and plating; fibroblasts 
were allowed to adhere for 1-2 hours at 37o C before non-adherent cells were washed off. 
Fibroblast identity was confirmed by immunostaining cultured cells for vimentin (goat, 
Santa Cruz #sc-7557, 1:100), CD45.2 (biotinylated mouse, BD Pharmingen #553771, 
1:100), and CD31 (rat, BD Pharmingen #553370, 1:100), followed by secondary antibody 
and streptavidin (Alexa Fluor 647 anti-goat IgG, Alexa Fluor 488 anti-rat IgG, Alexa Fluor 
555 streptavidin, all 1:100: Invitrogen #A-21447, A-11006, Thermo Fisher #S-21381 
respectively); fibroblasts were >99% vimentin-positive, with <5% CD45+ contaminants 
and no CD31+ cells present.  
For soft collagen gel cultures, fibroblasts were plated on thick 1 mg/ml type I 
collagen gels; type I rat tail collagen (Corning #354236) was diluted in 10X PBS and sterile 
ddH2O at 1 mg/ml and neutralized using 1 N NaOH per manufacturer’s instructions. 
Collagen gels were allowed to solidify for 1-3 hours prior to plating. Fibroblasts were 
plated onto collagen gels and cultured for 48 hours prior to phase contrast and multiphoton 
second harmonic generation (2P-SHG) imaging. 
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Acute deletion of calcineurin in vitro 
To acutely delete calcineurin B (CnB) in vitro, P1 CnBfl/fl fibroblasts were treated 
with 300 MOI AdCMV-Cre (U Iowa Viral Vector Core Facility) overnight in 10% serum 
media; culture media was washed out and cells were washed with PBS before replacing 
with fresh culture media and allowing the cells to recover for a day. Fibroblasts were 
passaged once prior to use in experiments; all fibroblasts were passage 3 at the time of use 
in experiments. Controls were either WT fibroblasts treated with AdCre, CnBfl/fl fibroblasts 
from the same isolation treated with AdGFP, or CnBfl/fl fibroblasts from the same isolation 
without viral transduction. CnB deletion was confirmed by Western blot for calcineurin A 
as described below. 
 
Proliferation assays 
For proliferation assays, fibroblasts were plated in gelatin-coated 24-well plates and 
serum-starved overnight. Day 0 counts were measured, then media was exchanged for 
either 1% or 10% FBS + DMEM-F12 culture media. On each measurement day, 3 wells 
per condition were trypsinized, and dead cells were stained with trypan blue before 
counting using a hemocytometer. EdU proliferation assays were performed on gelatin-
coated chamber slides using the Click-iT EdU Alexa Fluor 594 Imaging Kit (Invitrogen) 
according to manufacturer’s instructions; fibroblasts were pulsed with 10 µM EdU for 16-
18 hours prior to fixation and staining.  
 
In vitro scratch wound healing assays and live-cell imaging 
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Scratch assays were performed as described previously156. Briefly, cells were plated 
at 100% confluence in 12 well plates and allowed to adhere overnight. Cell layers were 
wounded using a P200 pipet tip, washed once with PBS, and replaced with DMEM-F12 
1% FBS culture media. 2 experimental replicates were imaged at 0, 2, 6, 12, 24, and 48 
hours post-wounding using an inverted microscope, and 2 replicates were imaged every 15 
minutes using a Nikon inverted microscope with a stage incubator for live cell imaging. 
Live cell imaging replicates were stained using the SiR-Hoechst far-red kit (Spirochrome 
#CY-SC007), and cell tracking was analyzed using Nikon NIS-Elements software. Each 
experimental condition was performed in triplicate. 
 
Transwell migration and invasion assays 
 For migration and invasion assays, 6.5mm (24 well) and 12mm (12 well) Transwell 
inserts with a pore size of 8 µm (Corning) were used respectively. 5 x 104 (6.5mm) or 7.5 
x 104 (12mm) WT or Cn-/- fibroblasts were plated into each transwell insert containing 
serum-free DMEM-F12 media in the upper chamber and 10% serum containing media in 
the lower chamber. For migration assays, inserts were uncoated; for invasion assays, inserts 
were coated with 75µl 1mg/ml neutralized type I rat tail collagen and allowed to gel for 1 
hour prior to cell seeding. For invasion assays, uncoated transwells were used as a positive 
control; for both migration and invasion assays, serum-free media was placed in the lower 
chamber as a negative control. 24 hours following plating, the upper chamber was wiped 
with a cotton swab to remove any unmigrated cells and washed with PBS; inserts were 
fixed and stained in fresh wells containing 0.5% crystal violet in 25% methanol solution 
for 15 minutes, washed by dipping in deionized water and allowed to dry completely before 
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imaging. Images were taken by inverting the insert onto a glass slide and tile-scanning 
using a Zeiss Axio Imager M2 upright microscope with Zen Pro software. The percentage 
of crystal violet-positive area on each insert was measured using ImageJ. Each assay was 
performed in triplicate, and experiments were repeated at least three times.  
 
2P-SHG imaging and analysis 
Images of fibroblasts cultured on collagen and FDMs were acquired using the Leica 
SP8 multiphoton upright confocal microscope available through the Penn Vet Imaging 
Core. Forward SHG signal was collected, and in non-cell-extracted cultures, 
autofluorescence in an adjacent channel was collected to identify cells and differentiate 
between SHG and non-SHG signal. 3-5 images per sample were taken for analysis, and Z-
stacks were performed to obtain maximum intensity projections through the thickness of 
the sample. Images were processed using LAS AF software. Where appropriate, collagen 
fiber analysis was performed using CT-FIRE and CurveAlign software; fiber alignment 
scores were generated in CurveAlign.  
 
Collagen contraction/remodeling assays 
Collagen gel contraction assays were performed as previously described127. Briefly, 
5 x 105 fibroblasts were embedded in 500 µl of 1 mg/ml rat tail type I collagen solution 
(Corning) in a 24 well plate. Collagen gels were allowed to solidify for 1 hour before the 
gels were detached and 500 µl of DMEM-F12 1% FBS culture media was added. Images 
were taken at 0, 6, 12, 24, 48, and 72 hours post-detachment using a gel documentation 
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system. Collagen gel areas were measured using ImageJ software; each time point was 
normalized to the area of an empty well. Assays were performed in triplicate. 
 
Measurement of collagenase activity using Type I DQTM Collagen 
To visualize collagenase activity, fibroblasts were cultured in chamber slides that 
were either coated with gelatin or a thick type I collagen gel as described previously (200 
µl/well). DQTM type I collagen from bovine skin conjugated to fluorescein (Invitrogen, 
#D12060) or DQTM gelatin from pig skin (Invitrogen, #D12054) was overlaid on cultures 
by adding to fresh culture media at 25 µg/ml. After 24 hours of incubation, cultures were 
fixed using Prefer glyoxal fixative (Anatech Ltd) or 4% paraformaldehyde (PFA) in PBS 
(Affymetrix/USB) and mounted/coverslipped using Fluorogel II with DAPI. Images were 
acquired using a Zeiss Axio Imager M2 upright fluorescent microscope and processed with 
Zen Pro software.  
 
Fibroblast-derived matrix (FDM) generation, extraction, and analysis 
FDMs were generated as per Cukierman et al.128. Briefly, 5 x 105 (35mm dish), 2 x 
105 (12 well plate), or 5 x 104 (35mm glass bottom dish) fibroblasts were plated onto 
gelatin-crosslinked dishes to 100% confluency. 75 µg/ml L-ascorbic acid (Sigma-Aldrich 
#A4544) was added to complete culture media and changed every other day for 8-10 days 
(35mm dish). Matrices were decellularized using 0.5% Triton X-100 and 20 mM NH4OH 
in PBS and stabilized at 4o C overnight before use. For analysis of earlier time points, 
FDMs were generated in triplicate in 12 well plates, and matrices were decellularized, 
extracted and solubilized following 3 and 5 days of ascorbic acid treatment. 
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To generate tumor cell-conditioned media, SR0144 lung tumor cells (generously 
provided by Dr. Carla Kim, Harvard University) were grown to 80% confluence, and 
culture media was replaced with serum-free DMEM for 24 hours. Conditioned media was 
centrifugated to remove all cells and insoluble material prior to use. Media for unstimulated 
and tumor-conditioned FDMs had a final serum concentration of 2.5% and consisted of a 
1:1 dilution of either tumor-conditioned media or serum-free DMEM with 5% FBS 
DMEM-F12, with a total concentration of 75 µg/ml L-ascorbic acid as above. 
 
Western blotting of cell lysates and FDMs 
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, 50 mmol/L Tris-
HCl pH 8, 150 mmol/L NaCl, 1% Triton-X, 0.5% sodium deoxycholate, and 0.1% SDS), 
centrifuged at 16,000 x g for 10 minutes, and supernatant was collected. Total protein 
content was quantified using BCA assay (Pierce). FDMs were solubilized in Protein 
Extraction Reagent Type 4 (Sigma-Aldrich C0356) and stored at -80 C until use. Protein 
loading of FDMs was normalized using the Bio-Rad Protein Assay Kit on samples diluted 
1:10. Total protein of FDMs was analyzed by running samples in 4x Laemmli sample 
buffer (Bio-Rad) on a 4-12% gradient gel (Invitrogen) and silver staining using a kit 
(Pierce). SDS-PAGE of lysates was performed using 3-10 µg per sample at 120-150 V on 
8, 10, or 12% gels depending on the size of the protein in question using the Bio-Rad Mini 
Protean Tetra Cell system. Proteins were transferred onto nitrocellulose or PVDF 
membranes at 90 V for 2 hours using the Bio-Rad Mini Trans-Blot system. Blots were 
blocked in 5% non-fat dry milk (LabScientific M-0841) in TBS-T (TBS + 0.1% Tween 20) 
and incubated with primary antibody diluted in blocking buffer at 4o C overnight 
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(calcineurin A: 1:2000, Abcam #ab3673; actin: 1:5000, Sigma #A2668). Blots were 
washed in TBS-T, and secondary antibody (anti-rabbit IgG HRP conjugate, Cell Signaling 
CST7074, 1:1000-1:5000) was incubated in blocking buffer for 1 h at room temperature 
then washed with TBS-T. Bands were visualized using enhanced chemiluminescence 
reagent (100 mM Tris pH 8.6, 0.2 mM p-coumaric acid, 1.25 mM luminol, 2.6 mM). 
 
Imaging analysis of cell behavior on FDMs 
104 WT or Cn-/- fibroblasts or MH6449 PDAC cells were plated in 35mm wells 
containing either WT or Cn-/- FDMs and allowed to adhere for 16 h before fixing with 4% 
PFA in PBS. Wells were blocked with 5% normal goat serum, 1% BSA, and 0.001% 
thimerosal in PBS, followed by Fc receptor blocking for 20 minutes (1:200, BD 
Pharmingen #553141). Primary antibodies were incubated in blocking buffer at 4o C 
overnight (paxillin: 1:100, BD Biosciences #612405), and secondary antibodies were 
incubated in 1% BSA in PBS for 1 h at RT. Following secondary antibody incubation 
(1:1000, Invitrogen #A-11032) cells were incubated with Alexa Fluor 488-conjugated 
phalloidin (1:40, Cell Signaling Technologies, #8878S) prior to mounting and 
coverslipping with Fluorogel II with DAPI. Confocal imaging was performed on a Leica 
TCS SP5 laser scanning confocal microscope and processed using LAS AF software. 
For live cell imaging studies, WT and Cn-/- FDMs were generated and 
decellularized in 12 well plates. 5 x 104 YFP+ MH6449 PDAC cells or 1 x 105 GFP+ 
primary lung ECs were plated onto decellularized matrices, and cell movement was tracked 
for 24 hours following plating using a Nikon inverted microscope with stage incubator for 
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live cell imaging. Individual cell tracking and velocity/direction analysis was performed 
using Nikon NIS-Elements software.  
 
Endothelial cell co-culture assays and angiogenic secretome analysis 
Primary GFP+ lung endothelial cells (ECs) were isolated as described previously165  
using CD31 MicroBeads (Miltenyi Biotec #130-097-148) and cultured in Advanced 
DMEM (Gibco) + 15% FBS, 25 mM HEPES, 0.1 mg/ml heparin, 100 µg/ml bovine 
endothelial growth supplement (Alfa Aesar #J64516), L-glutamine, and 
penicillin/streptomycin. On day 0 of the experiment, 2.5x105 each of fibroblasts and ECs 
were mixed 1:1 and embedded in growth factor reduced basement membrane extract 
(BME, Trevigen #3533-001-02) in 35mm glass bottom dishes. After 1 hour, organoid 
media (DMEM-F12, 10% KnockOut Serum Replacement (Gibco), 1x Insulin-Transferrin-
Selenium (Gibco), L-glutamine, penicillin/streptomycin) was added, and 3-5 phase-
contrast and fluorescence images per sample were taken at 0, 12, 24, 48, and 72 hours using 
an inverted tissue culture microscope with GFP filter. Tube formation was quantified by 
counting the number of tubes per high power field. Conditioned media for angiogenic 
secretome analysis was generated by culturing fibroblasts on BME in serum-free media for 
24 hours prior to collection. Conditioned media was analyzed using the Proteome Profiler 
Mouse Angiogenesis Array (R&D #ARY015). Conditioned media (750 µl/sample) was 
hybridized to membranes, and chemiluminescent signal was normalized to total protein 
content using lysate from fibroblast cultures. 
 
In vivo model of stromal-specific calcineurin deletion  
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The University of Pennsylvania Animal Care and Use Committee approved all 
studies. Mice with inducible stromal-specific deletion of calcineurin B were obtained by 
cross-breeding C57Bl/6 Cnb1fl/fl mice126 with C57Bl/6 Col1a1-Cre-ER(T) mice (JAX 
#016241) 133. Breeding cages were maintained using Cola1-Cre;CnBfl/fl crossed to CnBfl/fl 
in order to ensure hemizygosity of the Cre transgene. In order to acutely delete CnB in vivo, 
mice were given 1 mg tamoxifen in 100 µl corn or peanut oil (Sigma-Aldrich) 
intraperitoneally daily for 5 days, followed by 2 days without treatment. During tumor 
experiments, mice received 1-2 additional doses of tamoxifen per week to account for 
recruitment of bone marrow-derived stromal cells. Calcineurin deletion was confirmed by 
Western blot of isolated lung fibroblasts; lungs were dissociated and plated as described 
above, and after 30-60 minutes, non-adherent cells were removed and the adherent cell 
layer washed with PBS and collected in lysis buffer. 
To confirm Col1a1-Cre-ER(T) mRNA expression in lung fibroblasts, a portion of 
isolated lung fibroblasts were taken in Trizol, RNA extracted using the Dymo Direct-ZOL 
kit with on-column DNase digestion, and reverse transcription performed using the 
Applied Biosciences High Capacity cDNA Reverse Transcription Kit. A total of 200ng of 
cDNAs per qPCR reaction were added to 2x SYBR Green qPCR Master Mix (Bimake), 
and reactions were run and measured using the ViiA 7 Real-Time PCR System. Primers: 
GAPDH: forward 5’-AGGTCGGTGTGAACGGATTTG-3’ and reverse 5’- 
TGTAGACCATGTAGTTGAGGTCA-3’ and Col1a1-Cre: forward 5’-
CCAGCCGCAAAGAGTCTACA-3’ and reverse 5’-ACAATCAAGGGTCCCCAAAC-
3’. 
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Injection-resection model of lung metastasis 
Lewis lung carcinoma (LLC) cells were obtained from ATCC; MH6449 KPY 
PDAC cells were a generous gift from Dr. Ben Stanger at the University of Pennsylvania. 
Tumor cells were cultured in DMEM + 4 g/L glucose (Gibco), 10% heat-inactivated FBS 
(Gemini), L-glutamine (Gibco), and penicillin-streptomycin (Lonza). Tumor cells were 
passaged to be 70-80% confluent on the day of injection. Mice were 8-12 weeks at the time 
of tumor injection with the exception of one PDAC injection-resection experiment, in 
which mice were approximately 52 weeks of age and had been receiving tamoxifen weekly. 
Tumors were established by injecting 1x106 (PDAC) or 5x106 (LLC) tumor cells in 100 µl 
serum free DMEM subcutaneously into the right hind flank under isoflurane anesthesia. 
Tumors were measured using digital calipers, and volume was estimated using the ellipsoid 
volume equation V = ½ * width2 * length. Once tumors reached a volume of 400-600 mm3, 
they were resected under sterile conditions, and surgical sites were closed using 
nonabsorbable monofilament suture (Covidien). Tumors were flash-frozen in OCT 
immediately following resection. Mice received 5mg/kg Metacam (Boehringer Ingelheim) 
for 3 days following resection, and any dehisced surgical sites were re-sutured if necessary. 
14 days after resection, mice were euthanized and lungs were perfused with saline prior to 
dissection; lungs were dissected and either formalin-fixed for paraffin embedding or fixed 
in 4% PFA followed by incubation in 30% sucrose before freezing in OCT. FFPE samples 
were sectioned at 5 µM, and frozen samples were sectioned at 9-10 µM. Lung tumors were 
measured and normalized to total lung area using ImageJ software. 
 
Statistical analysis 
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Statistical analysis was performed using GraphPad Prism 7. P values were 
calculated using Student’s t-test (two-tailed, unpaired) or ANOVA where appropriate. 
 
Materials and Methods: Chapter 3 
TGF-b treatment of fibroblasts 
 Fibroblasts were treated with 0.5-10 ng/ml of pre-activated human TGF-b1 (R&D 
Systems). For the majority of activation studies, TGF-b was used at 2ng/ml. Because fetal 
bovine serum itself contains TGF-b, unless otherwise specified, studies were conducted in 
1% serum containing media to minimize the activating effects of the culture media in 
unstimulated conditions. 
Cytokine secretome array  
 Fibroblast-conditioned media was collected from fibroblasts cultured on soft 
1mg/ml type I collagen gels by replacing media with serum free culture media +/- 2 ng/ml 
TGF-b1 and collecting 24 hours later. Media was centrifuged to remove cells and 
particulate matter, and aliquots were flash-frozen and stored at -80 C until use. Secretome 
array analysis was performed using 750 µl of conditioned media according to kit 
instructions (R&D Systems). 
Analysis of TGF-b secretion/activation in scratch assays 
 In order to assess total TGF-b secretion and latent TGF-b activation, confluent 
fibroblast monolayers were either left unwounded or scratched in a cross-hatch pattern with 
a sterile plastic comb before being washed with PBS, and media was replaced with serum 
free culture media containing 30 ng/ml latent TGF-b1 (R&D Systems). Media was 
collected 24 hours later, centrifuged to remove cells and debris, flash-frozen on dry ice, 
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and stored at -80 C until use. Cell layers were lysed in RIPA buffer, and lysate protein 
concentration was determined by BCA for sample normalization. A sandwich ELISA kit 
for TGF-b1 (Enzo Biosciences) was used to determine both activated and total TGF content 
in conditioned media. For activated TGF, samples were used undiluted; for total TGF, 
samples were pre-activated with 1 N HCl according to kit instructions and diluted 1:10 in 
sample dilution buffer prior to use.  
Western blot of Smad2 phosphorylation 
 Western blots were performed as previously described. pSmad2: 1:1000, Cell 
Signaling; tSmad2/3: 1:1000, Cell Signaling. pSmad signal was assessed first, then blots 
were stripped by washing 3 x 15min in TBS-T before re-blocking in 5% milk and 
incubating with tSmad2/3 antibody. pSmad signal was visualized using Femto ECL reagent 
(Thermo Fisher); tSmad signal was visualized using previously described homemade ECL 
reagent. 
 
Materials and Methods: Chapter 4 
Polyacrylamide hydrogel assays and flow cytometry 
 Polyacrylamide hydrogels were generated according to the protocols created by Dr. 
Richard Assoian’s group.160 They were either acquired from the University of 
Pennsylvania ITMAT Core Facility or generated by myself according to their protocol. 
Hydrogels were coated with fibronectin solution at least overnight prior to use. Prior to 
plating, hydrogels were transferred with sterile forceps to tissue culture wells coated with 
1% agarose to prevent cell adhesion to the well. 40mm hydrogels were plated with 1.5x105 
(20-25 kPa) or 3.5x105 (2 kPa) fibroblasts depending on their stiffness; cells were cultured 
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for 48 hours in full serum media prior to use in downstream assays. For phalloidin imaging, 
12mm hydrogels were used, and cell numbers scaled down accordingly. Phalloidin staining 
was performed as described previously.  
For flow cytometry experiments, cells were collected via trypsinization and 
pelleted in a 96 well plate for all staining steps. Fibroblasts plated on plastic were used for 
single stain compensation controls and isotype antibody controls. All staining steps were 
performed in FACS buffer (2% FBS in PBS). Following 15 minutes of Fc block (1:200), 
primary antibody (biotinylated mouse anti-FAP, 1:124; isotype biotinylated mouse IgGK1, 
1:100, BD #550615) was incubated for 30 minutes at room temperature, followed by 
incubation with APC-conjugated streptavidin for 15 minutes (1:200). Live-dead staining 
was performed using the Fixable Violet Dead Cell Stain Kit (Molecular Probes). Cells were 
fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) prior to staining 
with FITC-aSMA antibody (1:270, Sigma #F3777; isotype FITC-IgG2a, 1:50). Samples 
were analyzed on an Attune NxT flow cytometer (Thermo Fisher).   
Intravenous tumor cell colonization assays 
SKPY42.1 tumor cells were obtained by isolating tumor cells from the sarcoma of 
a KPY (KrasG12D;p53fl/fl;Rosa26-LSL-YFP) mouse that had received AdCre injection in 
the hindlimb161; tumors were dissociated using the gentleMACS Octo with heating 
element, and cell suspensions were plated in 10% FBS DMEM and allowed to adhere 
overnight before washing the cell layer. Single cell clones of these tumor cell lines were 
obtained by serial dilution, and the subclones with the greatest invasive capability in in 
vitro Matrigel-coated Transwell assays were identified. Cells were cultured in 10% FBS 
 
 
97 
DMEM + 4 g/L glucose + L-glutamine + pen/strep and passaged to 70-80% confluence 
prior to use in experiments.  
CnBfl/fl and Col1a1-Cre;CnBfl/fl mice were treated with tamoxifen as described prior 
to use in tail vein injection assays. On the day of injection, 3x105 cells in 100 µl serum free 
DMEM were injected into the lateral tail vein of each mouse using a restrainer. Starting 
the day after tail vein injection, tamoxifen was continuously administered 2-3 times per 
week where noted. Mice were euthanized and lungs harvested at the indicated time points. 
Lung analysis was performed using H&E stained paraffin sections as described previously, 
and images were analyzed using ImageJ software.  
Bleomycin model of lung fibrosis 
 Mice were treated with tamoxifen as described previously prior to the start of the 
assay. For bleomycin lung fibrosis assays, a total of 5 doses of bleomycin (1 U per mouse 
in 400ul PBS for a dosage of 50 U/kg) were administered intraperitoneally every 5 days; 
mice were sacrificed 5 days after the final bleomycin injection. PBS was used as a vehicle 
for untreated controls. Lung analysis was performed using Masson’s trichrome stained 
paraffin sections, and images were analyzed using ImageJ software.  
Assessment of cutaneous wound healing 
 Mice were treated with tamoxifen as described previously prior to the start of the 
assay. Dermal wounds were generated on the dorsum of the mouse using bilateral 6mm 
punch biopsies under isoflurane anesthesia. Every other day, mice were briefly placed 
under isoflurane anesthesia, and wounds were imaged using a digital camera with a ruler 
for reference. Wounds were covered using non-adhesive gauze pads to prevent scabbing 
and interference with wound healing. This experiment was repeated a total of three times, 
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once without covering the wound and twice covering the wounds. Wound area was 
measured using ImageJ. 
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